* **Name of journal:** **World Journal of** **Gastroenterology**
* **ESPS Manuscript NO: 29925**
* **Manuscript Type: REVIEW**
* **Pancreatic stellate cell: Pandora’s box for pancreatic disease biology**
* Bynigeri RR *et al*. Pancreatic stellate cells in health and disease
* Ratnakar R Bynigeri, Aparna Jakkampudi, Ramaiah Jangala, Chivkula Subramanyam, Mitnala Sasikala, D Nageshwar Reddy, Rupjyoti Talukdar
* **Ratnakar R Bynigeri, Aparna Jakkampudi, Ramaiah Jangala, Chivkula Subramanyam, Mitnala Sasikala, D Nageshwar Reddy, Rupjyoti Talukdar,** Institute of Basic Sciences, Asian Healthcare Foundation, Hyderabad 500082, India
* **D Nageshwar Reddy, Rupjyoti Talukdar,** Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad 500082, India
* **Author contributions:** Bynigeri RR, Jakkampudi A and Jangala R conducted literature search, compiled references and drafted the paper; Mitnala S, Subramanyam C and Reddy DN contributed to manuscript drafting and provided intellectual input; Talukdar R conceived and designed the manuscript, verified content, contributed to manuscript drafting and approved the final manuscript.
* **Conflict-of-interest** **statement:** The authors declare no conflict of interest.
* **Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>
* **Manuscript source:** Invited manuscript

**Correspondence to: Rupjyoti Talukdar, MD,** Clinical Pancreatologist,Asian Institute of Gastroenterology, Clinician Scientist (Wellcome-DBT Fellow), Asian Healthcare Foundation, 6-3-661 Somajiguda, Hyderabad 500082, Telangana, India. [rup\_talukdar@yahoo.com](mailto:rup_talukdar@yahoo.com)

**Telephone:** +91-40-23378888

**Fax:** +91-40-23324255

**Received:** August 30, 2016

**Peer-review started:** August 31, 2016

**First decision:** October 10, 2016

**Revised:** November 9, 2016

**Accepted:** December 16, 2016

**Article in press:**

**Published online:**

**Abstract**

Pancreatic stellate cells (PSCs) were identified in the early 1980s, but received much attention after 1998 when the methods to isolate and culture them from murine and human sources were developed. PSCs contribute to a small proportion of all pancreatic cells under physiological condition, but are essential for maintaining the normal pancreatic architecture. Quiescent PSCs are characterized by the presence of vitamin A laden lipid droplets. Upon PSC activation, these perinuclear lipid droplets disappear from the cytosol, attain a myofibroblast like phenotype and express activation markers (*e.g.,* α-smooth muscle actin). PSCs maintain their activated phenotype via an autocrine loop involving different cytokines and contribute to progressive fibrosis in chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC). Several pathways (*e.g.,* JAK-STAT, Smad, Wnt signaling, Hedgehog *etc*.), transcription factors and miRNAs have been implicated in the inflammatory and profibrogenic function of PSCs. The role of PSCs goes much beyond fibrosis/desmoplasia in PDAC. It is now shown that PSCs are involved in significant crosstalk between the pancreatic cancer cells and the cancer stroma. These interactions result in tumour progression, metastasis, tumour hypoxia, immune evasion and drug resistance. This is the rationale for therapeutic preclinical and clinical trials that have targeted PSCs and the cancer stroma.

* **Key words:** Pancreatic stellate cells; Physiological functions; Pancreatic fibrosis; Pancreatic cancer stroma; Pancreatic stellate cells-cancer-stromal interactions; Therapeutic targets
* **© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Pancreatic stellate cells (PSCs) have emerged as one of the major effector cells in chronic pancreatitis and pancreatic ductal adenocarcinoma. In this review, we discuss the physiological function of PSCs and the profibrogenic mechanisms. We also discuss various pathways, transcription factors and miRNAs implicated in the inflammatory and profibrogenic functions mediated by PSCs. We further discuss the crosstalk among PSCs, pancreatic cancer cells and pancreatic cancer stroma and mechanisms that lead to cancer progression, metastasis, tumour hypoxia, immune evasion and drug resistance. We conclude with recent preclinical and clinical studies that have targeted PSCs and cancer stroma.

* Bynigeri RR, Jakkampudi A, Jangala R, Subramanyam C, Sasikala M, Reddy DN, Talukdar R. Pancreatic stellate cell: Pandora’s box for pancreatic disease biology. *World J Gastroenterol* 2016; In press
* **HISTORICAL PERSPECTIVES**
* Stellate cells were described for the first time in the perisinusoidal spaces of the liver by Karl Wilhelm Von Kupffer in 1876 and were called “Sternzellen” (meaning star shaped cells). Later in 1951, Ito described the presence of lipid droplet containing cells in the perisinusoidal spaces of the liver and named them “Ito cells”[1]. The Ito cells were shown to emit blue-green fluorescence due to the presence of vitamin A in the lipid droplets[2]. Later in 1971, the usage of multiple techniques provided unequivocal evidence that the “sternzellen” reported by Kupffer and “Ito cells” identified by Ito were the same cell type: the hepatic stellate cells (HSCs)[3,4]. In 1982, a cell type carrying vitamin A containing lipid droplets and exhibiting a transient blue-green fluorescence were described in mouse pancreas[5]. In 1991, the cells exhibiting the vitamin A autofluorescence were identified in the healthy pancreatic sections from humans and rats[6]. These are pancreatic stellate cells (PSCs), which localize the periacinar regions, with long cytoplasmic projections extending towards the basolateral aspects of the acinar cells. Later in 1998, the development of *in vitro* tools to isolate and culture the PSCs laid a strong foundation to characterize their basic biology[7,8]. These cells also surround the perivascular and periductal regions. Sustained PSC cultures have helped to decipher the crucial factors that act in the inflammatory mechanisms and their mechanistic role in the pancreatic fibrosis in chronic pancreatitic (CP) and pancreatic ductal adenocarcinoma (PDAC). However, in view of the challenges of limited viability of the PSCs in primary cultures, there had been several attempts to modify isolation and culture techniques. In this regard, techniques were developed to immortalize the normal and tumour associated PSCs. However, further validation studies will be required prior to their routine use in PSC research[9-12]. Interestingly, even though PSCs were associated primarily with the exocrine pancreas, a recent study has reported isolation of PSCs from rat and human pancreatic islets too. These cells demonstrated certain morphologic and functional differences from the conventional PSCs in terms of fewer lipid droplets, lower rates of proliferation, migration and easier activation[13,14].
* **BASIC BIOLOGY OF PANCREATIC STELLATE CELLS**
* ***Origin***
* The origin of PSCs is still being debated. Till date no direct studies have been executed to identify the origin of PSCs. However, the studies on the origin of HSCs have helped in gaining some insight into this aspect. Even though initially a neuroectodermal origin of PSCs was proposed, it was eventually negated in genetic cell lineage mapping studies[15]. A recent study forwarded refreshing evidence supporting a mesodermal origin of HSCs by using the conditional lineage analysis approach[16,17]. Since most of the characteristic features and functions that sketched the biology of PSCs are similar to HSCs, it is believed that even PSCs might have evolved from a mesodermal origin. Employing such similar tracer techniques might help in ascertaining the origin of PSCs.
* In the context of CP and PDAC, even though most of the proliferating PSCs are derived from the resident PSCs within the pancreas, a proportion of PSCs are thought to originate in the bone marrow. This was proposed in a novel sex mismatched study, which evidenced that even bone marrow (BM) derived cells may also contribute to PSC population in CP and PDAC apart from the resident cells of pancreas[18,19]. The speculation that bone marrow is another potential source of PSC was further supported by a recent study involving dibutylin chloride induced CP wherein a model of stable hematopoietic chimerism by grafting enhanced green fluorescence protein (eGFP)-expressing BM cells was used. In this study, 18% of the PSCs in the pancreas was found to originate from the bone marrow[20]. A recent study that used enhanced green fluorescent protein (EGFP)(+)CD45(-) cells transplanted from EGFP-transgenic mice in a carbon tetrachloride (CCL4) model suggested that infiltrating monocytes could also differentiate into stellate cells within the pancreas and liver under the influence of monocyte chemotactic protein-1 (MCP-1)[21].
* ***Morphologic characteristics***
* Most of the characteristic features exhibited by quiescent as well as activated PSCs have been determined based on *in vitro* studies using rat and human PSCs isolates. Cultured PSCs display prominent retinoic acid containing lipid droplets with perinuclear localization in the cytoplasm**.** These lipid droplets elicit a fugacious blue-green autofluorescence when exposed to UV light at 328 nm or 350 nm wavelength. The expression of glial fibrillary acidic protein (GFAP) and lipid droplets serve as markers for quiescent PSCs[5-8]. The underlying mechanisms involved in the accumulation and disappearance of lipid droplets are still not elaborately elucidated. It was demonstrated in a few studies that albumin colocalizes with the lipid droplets within quiescent PSCs. Activated PSCs, which are characterized by disappearance of lipid droplets, re-developed the lipid droplets and showed resistance against the activating effects of transforming growth factor-β (TGF-β) when transfected with the plasmids expressing albumin, thereby confirming the contribution of albumin on lipid droplet formation. The albumin was reported to be a downstream effector of peroxisome proliferator activated receptor-γ (PPAR-γ), a nuclear receptor that is known to inhibit PSC activation[22,23]. The presence of lipid droplets together with expression of GFAP, desmin, nestin and vimentin is used to differentiate the PSCs from pancreatic fibroblasts[24]. Using GFAP-*LacZ* transgenic mice model, it was proven that GFAP promoter activity was unique to PSCs alone in the pancreas[25].
* Autotransformation of quiescent PSCs to activated phenotype is observed in primary cultures. The basic phenotypic differences that were observed when the PSCs switch to activated phenotype include the disappearance of lipid droplets and transformation into a myofibroblast-like phenotype. The expression of α-smooth muscle actin (α-SMA) marks the transdifferentiation of the quiescent PSC to an activated phenotype. Figure 1 shows the morphology of PSCs in culture at different time points.
* ***PSC functions***
* The physiological and pathological functions of PSCs have been summarized in Table 1A and B respectively. Under physiological conditions**,** PSCs are believed to contribute to the exocrine cell structure and function *via* maintenance of the normal basement membrane[26,27] and carry out normal ductal and vascular regulation by virtue of their localization[28]. Quiescent PSCs have a low mitotic index and bears the capability to synthesize matrix proteins and maintain the physiological extracellular matrix. The expression of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) are complementary to each other and is a prerequisite to poise the ECM turnover. Increased production of the ECM proteins fibronectin, periostin, MMPs and TIMPs are the most common features exhibited by the activated PSC phenotype[29] and hence described as the effector cells contributing to the stroma associated with CP and PDAC. Besides laying and maintaining the ECM, PSCs have also been demonstrated to secrete acetylcholine that might function as an intermediate regulator for cholecystokinin mediated pancreatic exocrine secretion[30].
* Until recently, much attention was paid to unveil the functions of activated PSCs as a multiple cytokine producing profibrogenic cell type, which promotes self-proliferation, migration and fibrogenesis. However, recent advances have even demonstrated certain non-fibrogenic functions of PSCs, which projected PSCs as immune cells[31], intermediary cell[30,32] and also as a progenitor cell[33-35]. An earlier study showed that PSCs could phagocytize senescent neutrophils in experimental acute pancreatitis and this was reduced by the presence of cytokines while augmented by presence of PPAR-γ ligand[31]. The same group subsequently demonstrated that PSCs could also phagocytize necrotic acinar cells and themselves undergo cell death. No change in TGF-β concentration was detected in the PSC media and medium with PSC and acinar cells, thereby indicating that the death of PSCs could result in inhibition of fibrogenesis in the setting of AP[36]. This role in innate immunity was further supported by the capacity of PSCs to recognize pathogen-associated molecular patterns (PAMPS) *via* Toll-like receptors (TLRs) that are expressed their surface[37].
* Studies have now also proposed a regenerative role especially in the context of acute pancreatitis, where the interaction between extracellular matrix laid by PSCs and acinar surface integrin receptors could result in a scaffold for acinar regeneration. Excess matrix deposition could also potentially be ameliorated by matrix degrading enzymes and apoptosis/cytolysis of activated PSCs[38].
* In addition to the above-mentioned functions of PSCs, it is now becoming more evident that these multifunctional cells also affects endocrine secretion in CP. This speculation surfaced from experiments that demonstrated increased numbers of PSCs in rat pancreas in a Type 2 diabetic model[39]. Extension of this study *in vitro* showed that PSCs could reduce insulin secretion and induce β-cell apoptosis[40-42]. On the contrary, another study showed that PSCs increase insulin secretion from mouse islets[43]. Interestingly, INS-1 cell culture supernatants reduced the secretion of proinflammatory cytokines (that mediate β-cell dysfunction) and ECM proteins from PSCs[44]. Moreover, the expression of regenerating islet-derived protein-1 was high in islet stellate cells (ISCs) isolated from the diabetic mice, which inhibited the viability, migration, synthesis and secretion of ECM proteins in ISCs *in vitro*[45]. As the *in vitro* results are more divergent, meticulous studies need to be designed and executed to understand the precise role played by these cells during their reciprocal interaction.
* ***Fate of PSCs***
* The fate of activated PSCs is an important question that remains unresolved. Figure 2 depicts a schematic representation of the fates of PSCs. One of the two possible explanations that were proposed is that sustained inflammation may perpetuate PSC activation, leading to fibrosis; while the other explanation proposed that the activated PSCs may undergo apoptosis or may revert back to the native phenotype if the inflammation or injury is ceased. Recently, Fitzner *et al*[46] proposed that activated PSCs could undergo senescence as evidenced by increased senescence-associated β-galactosidase, higher expression of CDKN1A/p21, mdm2 and interleukin (IL)-6. On the contrary, there was lower expression of α-smooth muscle actin. The authors also observed that senescence increased the susceptibility of PSCs to cytolysis and concluded that inflammation, PSC activation and cellular senescence were coupled processes and took place in the same inflammatory microenvironment of CP[46]. In the setting of AP, PSCs could undergo death after phagocytizing necrotic acinar cells[36].

**PSCs AND FIBROSIS**

* A pathological hallmark of CP and PDAC is progressive fibrosis that is mediated by the PSCs. One of the earliest cellular events at the initiation of fibrosis is activation of PSCs, which can be mediated concomitantly by a variety of factors, such as oxidative stress, cytokines, growth factors, activin-A, angiotensin, hyperglycemia, pressure, to name a few. Interestingly, activation of PSCs can occur by both autocrine and paracrine mechanisms, which imply that the effects of PSC activation, primarily inflammation and resultant fibrosis can progress, even after removing the primary source. The distinctive sources of exogenous factors that actuate the PSC activation includeactivated macrophages, monocytes, pancreatic acinar cells, endothelial cells, pancreatic cancer cells and platelets in inflamed pancreas[47-50]. Figure 3 depicts the autocrine and paracrine mechanisms of PSC activation and the resulting fibrosis.
* ***Alcohol, smoking and PSC activation***
* Alcohol and smoking are now recognized as independent risk factors for the development of CP. It is known that pancreatic acinar cells can metabolize alcohol to form toxic metabolites that results in oxidative stress. This results in inflammation and PSCs activation[51,52,53]. Furthermore, PSCs themselves can metabolize ethanol to acetaldehyde and generate oxidative stress, thus promoting their own activation and lipid peroxidation. The above findings have been confirmed by immunostaining for 4-hydroxy-nonenal (4-HNE), a reactive product of lipid peroxidation, that demonstrated localization of 4-HNE stained PSCs in fibrotic areas adjacent to acinar cells[54-56]. Ethanol activated PSCs showed increased proliferation by enhancing the activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system stimulated by PDGF[57]. Also shown was expression of connective tissue growth factor (CCN2/CTGF) that was attributed to production of acetaldehyde and oxidant stress in ethanol stimulated PSCs, which rendered the properties of cell adhesion, migration and collagen synthesis when stimulated with profibrogenic molecules[58]. Recently, CCN2 was also shown to increase miR-21 expression that in turn enhanced collagen α1 expression in a murine alcoholic CP model. CCN2 and miR-21 were shown to be colocalized in PSC derived exosomes that were positive for cluster of differentiation (CD) 9. *In vitro* studies revealed that these exosomes serve as molecular cargos to activate and transfer fibrogenic signals to the adjacent PSCs[59].

Lee *et al*[60] has recently demonstrated that PSCs express nicotinic acetylcholine nAChRs (isoforms α3, α7, β, ε). Furthermore, nicotine and nicotine-derived nitrosamine ketone (NNK) and cigarette smoke extracts (CSE) were shown to activate PSCs both in the presence and absence of alcohol. This reiterates the clinical observation of role of smoking as an independent risk factor in the initiation and progression of CP[61].

***Pressure and PSC activation***

Ductal hypertension resulting from obstructing pancreatic ductal calculi or stricture has been long believed to be a major contributor of pain in CP. This formed the rationale for ductal clearance of stone/stricture by endotherapy and/or surgery in an attempt to ameliorate pain in CP. Experimental evidence to support this concept came forward from studies by Asaumi *et al*[62,63] where externally applied pressure of 80 mmHg induced activation of PSCs and generation of ROS within the activated PSCs. ROS generation was observed as early as 30 min after application of pressure and reached peak by 1 h.

***Hyperglycemia and PSC activation***

In a study by Ko et al., exposure of PSCs to high glucose concentration resulted in stimulation of α-SMA expression, proliferation and expression of extracellular matrix proteins such as CTGF and collagen type IV[64]. PSC activation by hyperglycemia was also confirmed by subsequent studies by Nokoyama *et al*[65] and Hong *et al*[39] and the latter study also suggested an additive effect of hyperglycemia and hyperinsulinemia in inducing PSC activation and islet fibrosis in the context of Type 2 diabetes. Observations from these studies have provided an insight into the role of hyperglycemia in preserving the activated phenotype and also in the context of secondary diabetes in patients with CP. A more recent study has indicated that hyperglycemia could result in induction of Cysteine-X-Cysteine ligand (CXCL) 12 production by the PSCs and its receptor, CXCR4 on cancer cells[66].

***Cytokines and other activation factors that mediate proinflammatory function of PSCs***

Fibrous tissue in CP and PDAC abounds in type I collagen. Among the cytokines that can cause PSC activation, TGF-β stands among the most important. Studies have shown increased collagen synthesis and upregulation of MMP1 in PSCs that were stimulated with TGF-β and TGF-α[67,68]. Other activators of PSCs include interleukin-8 (IL-8), MCP-1 and RANTES (Regulated on Activation, Normal T-cell Expressed and Secreted), which promote PSC activation via autocrine pathways[69]. Activin-A and angiotensin II have also been identified as the autocrine activators of PSCs, contributing to further TGF-β1 expression and PSC proliferation[70,71]. Expression of TGF-β1 and collagen secretion, has also been shown to result from application of external pressure and with hyperglycemia[63,64,65].

Migration and proliferation of PSCs are other important properties that go parallel along with the proinflammatory and profibrotic cascade. Proliferation and migration of PSCs is mediated by PDGF[57,72,73] (which is expressed after TGF-β mediated activation) and endothelin-1[74,75]. A proinflammatory chemokine, CX3CL1 (fractalkine), reported to circulate in the serum of patients with alcoholic chronic pancreatitis (ACP), was demonstrated as an activation and proliferation factor for PSCs and PSCs were shown to express the receptor (CX3CR1) for this chemokine[76,77]. Interestingly, this chemokine and its receptor system was reported to regulate the insulin secretion by β-cells[78]. Recently, another new activation factor, namely parathyroid hormone related protein (PTHrP) was demonstrated to be expressed by acinar cells during experimental pancreatitis using an acinar cell specific PTHrP gene knock-out model. Receptor for this factor (PHT1R) has been shown to be expressed in PSCs and receptor-ligand interaction between the two resulted in fibrogenesis[79]. Of note, IL-6 has been shown to inhibit both PSCs proliferation and collagen synthesis[80]. Recently it was also demonstrated that IL-4 and IL-13 secreted by PSCs mediate macrophage activation, which in turn participate in promoting the pancreatic fibrosis[81].

To summarize the effect of the above experimental evidence, different paracrine factors released during the injury will result in activation, proliferation and migration of PSCs and the activated phenotype is further retained by an autocrine loop, even in the absence of paracrine triggers.

**MOLECULAR PATHWAYS, MICRORNAS, TRANSCRIPTION FACTORS AND PROTEOMICS IN PSC MEDIATED PANCREATIC FIBROSIS**

* Studies conducted over the past decade have implicated the involvement of several proteins and molecular pathways (Figure 4) in perpetuating the profibrogenic role of PSCs.
* ***MAPK, JAK-STAT and PI3K signaling pathways***
* Mitogen activated protein kinases (MAPKs) are serine/threonine protein kinases with three families: extracellular signal regulated kinase (ERKs), c-Jun N-terminal kinase (JNK) and p38[82], and all the three MAPKs have been studied extensively for their role in PSCs activation. *In vitro* studies demonstrated that the activation of ERK1/2 is the initial pathway that precedes the transformation of PSCs into activated phenotype and PDGF was shown to mediate ERK1/2 and Activator protein-1 (AP-1) dependent proliferation and migration of PSCs[72,73]. Studies have also demonstrated involvement of the Janus-activated kinase-signal transducers and activators of transcription (JAK2-STAT3) pathway in PDGF-BB induced PSC proliferation[83]. PI3K and all the MAPKs were described in human PSCs to express IL-32α and IL-33 when treated with proinflammatory cytokines. IL-33 was shown to activate PSCs[84-86]. HNE was reported to activate all the 3 classes of MAPKs and AP-1. PSCs treated with HNE showed increased production of type I collagen with no significant effect on proliferation and transformation, implicating oxidative stress mediated pathogenesis of pancreatic inflammation and fibrosis[87]. All the three MAPKs including AP-1 were triggered in PSCs when stimulated with ethanol and acetaldehyde. Inhibition of p38, JNK and Rho-Rho associated protein kinase (ROCK) pathways demonstrated the inhibition of PSC activation, supporting the involvement of above mentioned pathways in the pathogenesis of alcohol induced pancreatic injury[54,88,89].
* ***Smad signaling pathway***
* TGF-β1, which is a proven profibrogenic cytokine, is required in the regulation of PSC activation[90]. Smads are the signaling effectors of TGF-β mediated functions and have also been ascribed a regulatory role in PSC functions. Results from co-expression of Smad2/3 with dominant negative Smad2/3 mutants and inhibition of ERK showed that the activation, proliferation and TGF-β1 mRNA expression are mediated through the Smad2/3 and ERK dependent pathways in PSCs[91]. The autocrine loop between IL-1β and TGF-β1 and the one existing between the IL-6 and TGF-β1 were mediated by Smad3/ERK dependent and Smad2/3 and ERK dependent pathways. Further investigations had confirmed the existence of a TGF-β1 autocrine loop and supported the role of PSCs in preserving the activated phenotype and collagen synthesis[92,93]. TGF-β1 induced expression of cyclooxygenase-2 (COX-2) by PSCs also followed Smad2/3 dependent pathway in response to proinflammatory cytokines[94]. This pathway has been suggested to be protective against the inhibitory activity of Reversion-inducing-cysteine-rich protein with kazal motifs (RECK), a membrane anchored MMP inhibitor in the activated PSCs[95]. The stimulation of activated PSCs with TGF-β unveiled the possible role of Ras-ERK and PI3/Akt pathways in the expression of MMP-1[68].
* ***Wnt signaling and β-catenin pathway***
* Yet another signaling pathway aberration that could result in PSC activation, proliferation and transformation into a profibrotic phenotype is that of Wnt signaling. This observation came from an experimental CP model by Hu *et al*[96] where the authors have shown that there was increased expression of Wnt and its second messenger β-catenin and that this imbalance could result in persistent activation of PSCs. Yet another study by Xu et al. showed that cancer cell invasion and migration are promoted by Wnt2 protein secreted by the PSCs[97].
* ***Hedgehog signaling pathway***
* Indian hedgehog (IHH) and sonic hedgehog (SHH) are the other important pathways in PSCs. Receptors, namely smoothened and patched-1, for the IHH protein are expressed on the surface of PSCs and the receptor-ligand binding results in localization of the membrane-type 1 matrix metalloproteinase (MT1-MMP) on PSC plasma membrane, which in turn could mediate PSC migration[98]. SHH was shown to influence the PSC mobility and differentiation[99] and also perineural invasion, metastasis, tumour growth and pain in pancreatic cancer[100,101].
* ***microRNAs***
* Implications on the involvement of microRNAs (miRs) has recently being reported frequently in the context of CP and PSCs. A recent study has reported upregulation and downregulation of 42 miRs each in activated PSCs[102]. miR-15b and 16 have been shown to induce apoptosis of rat PSCs *via* influencing the anti-apoptotic Bcl-2 protein[103]. An even more recent study demonstrated a paracrine pathway wherein CCN2 mRNA and miR-21 containing exosomes liberated by PSCs were engulfed by surrounding PSCs. This results in further expression of the CCN2 and miR-21 by the activated PSCs[59].
* ***Transcription factors and interactions with cytokines***
* Different cytokines exert their effect by inducing various transcription factors such as nuclear factor-κB (NF-κB), Activator protein-1 (AP-1), STAT proteins and Gli, to name a few. NF-κB is stimulated by various cytokines associated with different cellular functions[104]. Activated PSCs showed NF-κB mediated expression of intracellular adhesion molecule (ICAM-1) when stimulated with IL-1β and tumor necrosis factor (TNF)-α, which was not observed in the quiescent phenotype[105]. Expression of MCP-1, cytokine induced neutrophil chemoattractant-1 (CINC-1), IL-6, IL-8 and RANTES was observed via NF-κB activation when induced with galectin-1, various ligands of TLR and cytokines, substantiating the role of PSCs in mediating the infiltration and accumulation of inflammatory cells[106-108].
* ***Proteomics***
* Proteomic studies using the immortalized PSC lines from *Mus musculus* and *Rattus norvegicus* showed the expression of cytoskeletal and ribosomal proteins by activated PSCs. The studies also demonstrated proteins involved in protein degradation, MAP Kinase 3 and Ras related proteins by pseudo-quiescent PSCs[109,110]. Proteomic profiling of mild and severe CP by label free quantitative proteomic approach displayed varied expression of proteins with a relative change in the proteins related to ECM and PSC activation which includes periostin, fibrillin 1, transgelin and a group of collagens. An accompanying study showed increased expression of transgelin in stromal and periacinar regions of CP, confirming its role in PSC activation[111,112].
* A comparative proteomic profiling of human HSC and PSC lines LX-2 and RLT-PSCs identified 1223 different proteins. Among 1223 proteins 1222 were found to be commonly expressed in both cell lines and a single protein (amino transferase) was found only in HSCs. The proteins in abundance from human PSC lines in this study were implicated for their role in maintaining the cellular structure[113]. The proteomic analysis of nicotine treated human, mouse and rat PSCs by GeLC-MS/MS approach demonstrated the differential expression of proteins and signaling pathways, while the expression of integral protein 2B, procollagen type VI alpha, toll interacting protein and amyloid interacting proteins was found to be common[114]. Expression of lysosomal proteins, indicators of pancreatic disease, proteins involved in defense mechanism and alteration in the phosphorylation sites was observed in another study[115]. Few other proteomic studies of similar kind have reported the expression of proteins related to inflammation, fibrosis, apoptosis, wound healing and proliferation[116]. The change in the expression profile of the proteome in response to various (TNF-α, FGF-2, CCL4 and IL-6) proinflammatory factors on immortalized human PSCs described their unique functions[117].
* **PSCs-PANCREATIC CANCER CELLS- CANCER STROMAL INTERACTIONS**

It has now been conclusively demonstrated that majority (50%-80%) of PDAC volume is composed of a fibrous stroma, amidst which lay the islands of cancer cells[118]. There has been increasingly accumulating evidence that supports substantial two-way interactions between the stromal components and cancer cells and the association between the cancer cells and cancer associated PSCs have received several monikers such as “*dangerous liaisons*”[119], “*friends or foe*”[120] and “*unholy alliance*”[121]. The stroma in pancreatic cancer consists predominantly of collagenous fibres laid down by the PSCs, along with other cellular (mast cells, macrophages, lymphocytes, myeloid derived suppressor cells [MDSC] and endothelial cells)[122-131] and non-cellular (ECM proteins such as collagen, laminin, fibronectin, glycoproteins, proteoglycans and glycosaminoglycans; non-ECM proteins such as growth factors, osteopontin, periostin and serine protein-acidic and rich in cysteine [SPARC]) components[132,133]. These stromal components can mediate the interaction between the PSCs and cancer cells and eventually influence the biological behavior and clinical outcomes of PDAC. Apart from vascular endothelial growth factor (VEGF) and angiopoietin-1, PSCs also secrete hepatocyte growth factor (HGF) and mediators responsible for endothelial cell proliferation and tube formation. This appears to operate through the (HGF)/c-MET pathway via induction of the downstream PI3K and p38 signaling pathways[134].Of note, upon neutralizing the HGF activity, proliferation and migration of cancer cells could be inhibited and apoptosis could be induced[135].

Even though fibrosis that was observed early in development of PDAC led to the belief that PSC produced stroma is protective, this eventually shifted towards the concept of the stroma having a tumour permissive effect. However, the current opinion holds that PSC-stroma-cancer cell interaction is dynamic and stage-dependent, with protective effect in the earliest stage while harmful effect in later stages[38]. The mechanism of PSC induced fibrosis in PDAC is similar to that seen in CP. Therefore, in the next section we will discuss only the cancer specific interactions and phenotypic effects of stroma-cancer cell interactions. While the PSC-pancreatic cancer cell interactions result in cancer growth and PSC activation, interaction between PSCs and stromal cells may be instrumental in metastasis, immune evasion, tumour hypoxia and resistance to chemoradiotherapy.

***PSC-PDAC crosstalk***

Pancreatic intraepithelial neoplasia (PanINs) are the precursor lesions of PDAC. It is now well known that PSCs get activated even at the early PanIN stages of PDAC and initiates fibrosis around these precursor lesions. Several *in vitro* and *in vivo* studies have provided insight into the bipolar interactions between the PSCs and PDAC. *In vitro* co-culturing of PSCs with pancreatic cancer cells accelerated the proliferation and increased survival by inhibiting apoptosis[49,136]. Furthermore, co-culturing also resulted in epithelial to mesenchymal transformation (EMT) as evidenced by increased expression of vimentin and snail (mesenchymal marker) with corresponding reduction in E-cadherin and cytokeratin (both epithelial markers)[137]. This was associated with migration of the cancer cells, which indicates the capability of PSC to trigger metastasis of pancreatic cancer cells[138].

Recurrence of PDAC after therapy has been postulated to be an effect of persistence of a treatment resistant cancer stem cell niche. PSCs have been shown to regulate the genesis of a cancer stem cell niche as marked by increased expression of stem cell markers such as ABCG-2, Lin28 and nestin, while also attaining capability to form spheroids *in vitro*[139]. Interestingly, it has been shown that the same PDAC can contain a heterogeneous population of PSCs based on the expression of CD10, which is a cell-membrane associated MMP. CD10(+) cells are associated with a higher propensity to proliferate and invade, thereby indicating that the relative proportion of PSC subtypes could also determine the disease biology and prognosis[140].

While the foregoing paragraphs discussed the effect of PSCs on pancreatic cancer cells, the cancer cells also induce profound effects on the PSCs. Pancreatic cancer cells produce factors such as PDGF, trefoil factor 1[141] and COX-2, which could induce PSC proliferation. COX-2 expression is upregulated not only in the cancer cells, but also in the PanINs and PSCs exposed to conditioned medium from cancer cell lines[142-145]. Galectin-1 and Galectin-3, members of galectin family of β-galactoside binding proteins, are also important drivers of the PSC-PDAC crosstalk. Galectin-3 expression by pancreatic cancer cell lines was found to promote its own proliferation along with PSCs[146,147]. Figure 5 outlines the overall crosstalk between PSCs and pancreatic cancer cells.

***Role of PSCs******on invasion and metastasis***

Galectin-3[147], thrombospondin-2 (TSP-2) [148], stromal cell derived factor (SDF-1) [149] and nerve growth factor (NGF) [150] expressed by PSCs are shown to drive the invasion of PDACs. Studies on xenograft models showed that PSCs exert a modulatory function and potentiate the invasiveness of SUIT2 pancreatic cancer cells expressing serine protease inhibitor nexin2 (SERPINE2)[151,152]. Pancreatic cancer cells and PSCs express fibroblast growth factor (FGF) and fibroblast growth factor receptor (FGFR) that have been shown to mediate interaction between the tumour and stromal cells resulting in development of an invasive phenotype[153]. A recent study confirmed that pro-invasive character results from nuclear localization of FGFR1 and FGF2 in PSCs[154]. Perhaps the most convincing and concept changing data on the role of PSCs in metastasis was reported in the study by Xu *et al*[155] which showed that the PSCs could rapidly acquire a tumour inductive property even after a short exposure of pancreatic cancer cells, thereby facilitating tumour growth and metastasis. The authors used a gender mismatch approach in which they injected a combination of female pancreatic cancer cells and male human PSCs into the pancreas of female nude mice. Interestingly, they could demonstrate Y-chromosome positive (*i.e.,* the injected male human PSCs) in metastatic liver nodules. This implied that the PSCs from the liver could intravasate blood vessels, transport in circulation and extravasate into metastatic nodules alongside the metastatic cancer cells. The findings also suggest that the metastatic PSCs could mount an active stromal reaction even in the metastatic nodule. The property of transendothelial migration of the PSCs was further supported by *in vitro* studies and was found to be mediated by PDGF.

Besides contributing to distant metastasis, PSCs have also been implicated in neural invasion. This notion has been supported by studies that reported expression of neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) and stimulation of neurite formation towards pancreatic cancer cells by activated PSCs. These effects appear to be mediated by the sonic hedgehog paracrine signaling pathway[100,101].

* ***Tumour hypoxia and resistance***
* Similar to CP, PDAC is also characterized by hypoxic microenvironment. Tumour hypoxia arising from fibro-inflammatory environment is shown to induce the expression of hypoxia-inducible factor-1α (HIF-1α) and stimulate the secretion of SHH ligand by cancer cells, leading to stromal deposition by tumour associated fibroblasts. Organotypic culture of thick pancreatic sections under hypoxic conditions depicted the activation (α-SMA) and proliferation (Ki67) of PSCs along with higher expression of HIF-1α, mediating the activation of hypoxic pathways[156].  *In vitro* studies on the role of hypoxic milieu on the interactions between PSCs and PDACs led to interesting observations. The hypoxia exposed PSCs expressed type I collagen and VEGF, showed increased migration and also promoted the endothelial cell proliferation, migration and angiogenesis[157]. Another study also yielded similar results where the hypoxia induced PSCs showed increased expression of periostin, collagen type I, VEGF and fibronectin. In co-cultures, the hypoxia treated PSCs enhanced the endostatin production by cancer cells and increased the endothelial cell growth[158]. A similar kind of study using 3D matrices also reported that the hypoxia induced procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) in PSCs promotes cancer cell migration[159]. Periostin, a matrix protein, with its persevered autocrine loop was shown to promote ECM synthesis and cancer cell growth under hypoxia and starvation during chemotherapy by maintaining the activated phenotype of PSCs[160]. PSCs were also shown to express miRNA-21 and miRNA-210 under hypoxic conditions, where miRNA-210 was reported to regulate the interactions between PSCs and PDACs via ERK and Akt pathways[161] and miRNA-21 contributing to cancer cell invasion and metastasis[162]. Apart from these 2 miRNAs, miRNA-199a and miRNA-214 expressed by PSCs shown to have a pro-tumoral effect and also promote their own proliferation and migration[163]. Overexpression of miR-29, the expression of which was lost during the transformation of PSCs into activated phenotype, resulted in the reduction of collagen deposition, cancer cell growth and viability[164].
* The outcomes of the above studies not only confirmed the central role of PSCs in desmoplasia but also exhibited the proangiogenic functions mediated by them in tumour hypoxia.
* ***Immune escape of PDAC***
* Emerging data over the recent years have strongly suggested that pancreatic cancer cells could evade host immune surveillance. One of the major factors that mediate immune evasion of pancreatic cancer cells is by sequestration of CD8(+) cells within the stroma, thereby preventing them from invading peritumoral areas where they could mediate immune mediated injury to the cancer cells. This appears to be mediated by the chemokine CXCL12[165]. The other important mediator that sustain an immunosuppressive milieu is the β-galactoside binding lectin galectin-1, which is overexpressed by PSCs in pancreatic cancer. Using siRNA induced knockout and overexpression studies, it was shown that galectin-1 could induce T-cell apoptosis and reduced Th-1 response (with concomitant increase in Th-2 responses) and thereby reducing the immune mediated injury to the cancer cells. This was further reconfirmed and was shown that the effects were significantly higher in poorly differentiated tumours compared to the well-differentiated ones[166].
* Other PSC mediated mechanisms that has been proposed to result in disruption of anti-tumour immunity are cytokine secretion by macrophages[167] and expression of the fibroblast activation protein-α (FAP-α)[168], migration of myeloid-derived suppressor cells[130], mast cell degradation leading to release of tryptase and IL-13[124].
* **THERAPEUTIC IMPLICATIONS**

Given the background of substantial understanding of the mechanisms of PSC involvement in pancreatic fibrosis and pancreatic cancer, several experimental, preclinical and early phase clinical studies on CP and pancreatic cancer have appeared in the literature over the recent years. Experimental studies (both *in vivo* and *in vitro*) that have targeted the profibrogenic function of PSCs have shown favorable results; however these results have not yet been satisfactorily reproduced in human CP. Table 2 shows the drugs and their effects in experimental studies of CP[169-218].

In the context of pancreatic cancer, where conventional chemotherapy has shown dismal results, the current concept is to target the stroma along with conventional chemotherapy. Since the pancreatic cancer stroma has been shown to be associated with tumour hypoxia, metastasis, drug resistance, it is expected that prior stromal degradation could result in chemosensitivity of the tumour even with the conventional chemotherapeutic drugs. Table 3 shows the recently tested drugs/biologics that targeted pancreatic cancer stroma in preclinical studies[219-242]. Besides the preclinical studies, several Shh pathway inhibitors have also been tested in advanced or metastatic PDACs in phase I and II studies (both open labeled and randomized double-blind controlled trials). Few of these include Vismodegib (GDC-0449), Saridegib (IPI-926) and Erismodegib (LDE225), PDGFR inhibitor (TKI258), hyaluran (PEGPH20), dasatinib, to name a few. These have been used along with gemcitabine and/or nab-Paclitaxel and FOLFIRINOX. Discussion of details of the study designs and results of these trials are out of the scope of this review and can be obtained from recent high quality reviews[243,244].

**REFERENCES**

1 **Ito T.** Cytological studies on stellate cells of Kupffer and fat storing cells in the capillary wall of the human liver. *Acta Anat Nippon* 1951; **26**: 42

2 **Wake K**. Development of vitamin A-rich lipid droplets in multivesicular bodies of rat liver stellate cells. *J Cell Biol* 1974; **63**: 683-691 [PMID: 4421899 DOI: 10.1083/jcb.63.2.683]

3 **Wake K**. "Sternzellen" in the liver: perisinusoidal cells with special reference to storage of vitamin A. *Am J Anat* 1971; **132**: 429-462 [PMID: 4942297 DOI: 10.1002/aja.1001320404]

4 **Wake K**, Motomatsu K, Senoo H. Stellate cells storing retinol in the liver of adult lamprey, Lampetra japonica. *Cell Tissue Res* 1987; **249**: 289-299 [PMID: 3621303 DOI: 10.1007/BF00215511]

5 **Watari N**, Hotta Y, Mabuchi Y. Morphological studies on a vitamin A-storing cell and its complex with macrophage observed in mouse pancreatic tissues following excess vitamin A administration. *Okajimas Folia Anat Jpn* 1982; **58**: 837-858 [PMID: 7122019 DOI: 10.2535/ofaj1936.58.4-6\_837]

6 **Ikejiri N**. The vitamin A-storing cells in the human and rat pancreas. *Kurume Med J* 1990; **37**: 67-81 [PMID: 2255178 DOI: 10.2739/kurumemedj.37.67]

7 **Apte MV**, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, Pirola RC, Wilson JS. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. *Gut* 1998; **43**: 128-133 [PMID: 9771417 DOI: 10.1136/gut.43.1.128]

8 **Bachem MG**, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grünert A, Adler G. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. *Gastroenterology* 1998; **115**: 421-432 [PMID: 9679048 DOI: 10.1016/S0016-5085(98)70209-4]

9 **Masamune A**, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Establishment and characterization of a rat pancreatic stellate cell line by spontaneous immortalization. *World J Gastroenterol* 2003; **9**: 2751-2758 [PMID: 14669327 DOI: 10.3748/wjg.v9.i12.2751]

10 **Sparmann G**, Hohenadl C, Tornøe J, Jaster R, Fitzner B, Koczan D, Thiesen HJ, Glass A, Winder D, Liebe S, Emmrich J. Generation and characterization of immortalized rat pancreatic stellate cells. *Am J Physiol Gastrointest Liver Physiol* 2004; **287**: G211-G219 [PMID: 14977634 DOI: 10.1152/ajpgi.00347.2003]

11 **Jesnowski R**, Fürst D, Ringel J, Chen Y, Schrödel A, Kleeff J, Kolb A, Schareck WD, Löhr M. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. *Lab Invest* 2005; **85**: 1276-1291 [PMID: 16127427 DOI: 10.1038/labinvest.3700329]

12 **Rosendahl AH**, Gundewar C, Said Hilmersson K, Ni L, Saleem MA, Andersson R. Conditionally immortalized human pancreatic stellate cell lines demonstrate enhanced proliferation and migration in response to IGF-I. *Exp Cell Res* 2015; **330**: 300-310 [PMID: 25304103 DOI: 10.1016/j.yexcr.2014.09.033]

13 **Zha M**, Li F, Xu W, Chen B, Sun Z. Isolation and characterization of islet stellate cells in rat. *Islets* 2014; **6**: e28701 [PMID: 25483957 DOI: doi.org/10.4161/isl.28701]

14 **Zha M**, Xu W, Jones PM, Sun Z. Isolation and characterization of human islet stellate cells. *Exp Cell Res* 2016; **341**: 61-66 [PMID: 26546984 DOI: 10.1016/j.yexcr.2015.11.002]

15 **Cassiman D**, Barlow A, Vander Borght S, Libbrecht L, Pachnis V. Hepatic stellate cells do not derive from the neural crest. *J Hepatol* 2006; **44**: 1098-1104 [PMID: 16458991 DOI: 10.1016/j.jhep.2005.09.023]

16 **Asahina K**, Tsai SY, Li P, Ishii M, Maxson RE, Sucov HM, Tsukamoto H. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. *Hepatology* 2009; **49**: 998-1011 [PMID: 19085956 DOI: 10.1002/hep.22721]

17 **Asahina K**, Zhou B, Pu WT, Tsukamoto H. Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. *Hepatology* 2011; **53**: 983-995 [PMID: 21294146 DOI: 10.1002/hep.24119]

18 **Marrache F**, Pendyala S, Bhagat G, Betz KS, Song Z, Wang TC. Role of bone marrow-derived cells in experimental chronic pancreatitis. *Gut* 2008; **57**: 1113-1120 [PMID: 18367560 DOI: 10.1136/gut.2007.143271]

19 **Scarlett CJ**, Colvin EK, Pinese M, Chang DK, Morey AL, Musgrove EA, Pajic M, Apte M, Henshall SM, Sutherland RL, Kench JG, Biankin AV. Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. *PLoS One* 2011; **6**: e26088 [PMID: 22022519 DOI: 10.1371/journal.pone.0026088]

20 **Sparmann G**, Kruse ML, Hofmeister-Mielke N, Koczan D, Jaster R, Liebe S, Wolff D, Emmrich J. Bone marrow-derived pancreatic stellate cells in rats. *Cell Res* 2010; **20**: 288-298 [PMID: 20101265 DOI: 10.1038/cr.2010.10]

21 **Ino K**, Masuya M, Tawara I, Miyata E, Oda K, Nakamori Y, Suzuki K, Ohishi K, Katayama N. Monocytes infiltrate the pancreas via the MCP-1/CCR2 pathway and differentiate into stellate cells. *PLoS One* 2014; **9**: e84889 [PMID: 24416305 DOI: 10.1371/journal.pone.0084889]

22 **Kim N**, Yoo W, Lee J, Kim H, Lee H, Kim YS, Kim DU, Oh J. Formation of vitamin A lipid droplets in pancreatic stellate cells requires albumin. *Gut* 2009; **58**: 1382-1390 [PMID: 19293176 DOI: 10.1136/gut.2008.170233]

23 **Kim N**, Choi S, Lim C, Lee H, Oh J. Albumin mediates PPAR-gamma or C/EBP-alpha-induced phenotypic changes in pancreatic stellate cells. *Biochem Biophys Res Commun* 2010; **391**: 640-644 [PMID: 19932685 DOI: 10.1016/j.bbrc.2009.11.112]

24 **Omary MB**, Lugea A, Lowe AW, Pandol SJ. The pancreatic stellate cell: a star on the rise in pancreatic diseases. *J Clin Invest* 2007; **117**: 50-59 [PMID: 17200706 DOI: 10.1172/JCI30082]

25 **Ding Z**, Maubach G, Masamune A, Zhuo L. Glial fibrillary acidic protein promoter targets pancreatic stellate cells. *Dig Liver Dis* 2009; **41**: 229-236 [PMID: 18602878 DOI: 10.1016/j.dld.2008.05.001]

26 **Riopel MM**, Li J, Liu S, Leask A, Wang R. β1 integrin-extracellular matrix interactions are essential for maintaining exocrine pancreas architecture and function. *Lab Invest* 2013; **93**: 31-40 [PMID: 23069938 DOI: 10.1038/labinvest.2012.147]

27 **Means AL**. Pancreatic stellate cells: small cells with a big role in tissue homeostasis. *Lab Invest* 2013; **93**: 4-7 [PMID: 23269285 DOI: 10.1038/labinvest.2012.161]

28 **Masamune A**, Watanabe T, Kikuta K, Shimosegawa T. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. *Clin Gastroenterol Hepatol* 2009; **7**: S48-S54 [PMID: 19896099 DOI: 10.1016/j.cgh.2009.07.038]

29 **Phillips PA**, McCarroll JA, Park S, Wu MJ, Pirola R, Korsten M, Wilson JS, Apte MV. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. *Gut* 2003; **52**: 275-282 [PMID: 12524413 DOI: 10.1136/gut.52.2.275]

30 **Phillips PA**, Yang L, Shulkes A, Vonlaufen A, Poljak A, Bustamante S, Warren A, Xu Z, Guilhaus M, Pirola R, Apte MV, Wilson JS. Pancreatic stellate cells produce acetylcholine and may play a role in pancreatic exocrine secretion. *Proc Natl Acad Sci U S A* 2010; **107**: 17397-17402 [PMID: 20852067 DOI: 10.1073/pnas.1000359107]

31 **Shimizu K**, Kobayashi M, Tahara J, Shiratori K. Cytokines and peroxisome proliferator- activated receptor gamma ligand regulate phagocytosis by pancreatic stellate cells. *Gastroenterology* 2005; **128**: 2105-2018 [PMID: 15940641 DOI: 10.1053/j.gastro.2005.03.025]

32 **Berna MJ**, Seiz O, Nast JF, Benten D, Bläker M, Koch J, Lohse AW, Pace A. CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production. *J Biol Chem* 2010; **285**: 38905-38914 [PMID: 20843811 DOI: 10.1074/jbc.M110.125534]

33 **Mato E**, Lucas M, Petriz J, Gomis R, Novials A. Identification of a pancreatic stellate cell population with properties of progenitor cells: new role for stellate cells in the pancreas. *Biochem J* 2009; **421**: 181-191 [PMID: 19379129]

34 **Docherty K**. Pancreatic stellate cells can form new beta-like cells. *Biochem J* 2009; **421**: e1-e4 [PMID: 19552623 DOI: 10.1042/BJ20090779]

35 **Kordes C**, Sawitza I, Götze S, Häussinger D. Stellate cells from rat pancreas are stem cells and can contribute to liver regeneration. *PLoS One* 2012; **7**: e51878 [PMID: 23272184 DOI: 10.1371/journal.pone.0051878]

36 **Tahara J**, Shimizu K, Shiratori K. Engulfment of necrotic acinar cells by pancreatic stellate cells inhibits pancreatic fibrogenesis. *Pancreas* 2008; **37**: 69-74 [PMID: 18580447 DOI: 10.1097/MPA.0b013e318160a5cb]

37 **Nakamura T**, Ito T, Oono T, Igarashi H, Fujimori N, Uchida M, Niina Y, Yasuda M, Suzuki K, Takayanagi R. Bacterial DNA promotes proliferation of rat pancreatic stellate cells thorough toll-like receptor 9: potential mechanisms for bacterially induced fibrosis. *Pancreas* 2011; **40**: 823-831 [PMID: 21747311 DOI: 10.1097/MPA.0b013e318224a501]

38 **Apte M**, Pirola RC, Wilson JS. Pancreatic stellate cell: physiologic role, role in fibrosis and cancer. *Curr Opin Gastroenterol* 2015; **31**: 416-423 [PMID: 26125317 DOI: 10.1097/MOG.0000000000000196]

39 **Hong OK**, Lee SH, Rhee M, Ko SH, Cho JH, Choi YH, Song KH, Son HY, Yoon KH. Hyperglycemia and hyperinsulinemia have additive effects on activation and proliferation of pancreatic stellate cells: possible explanation of islet-specific fibrosis in type 2 diabetes mellitus. *J Cell Biochem* 2007; **101**: 665-675 [PMID: 17212361 DOI: 10.1002/jcb.21222]

40 **Kikuta K**, Masamune A, Hamada S, Takikawa T, Nakano E, Shimosegawa T. Pancreatic stellate cells reduce insulin expression and induce apoptosis in pancreatic β-cells. *Biochem Biophys Res Commun* 2013; **433**: 292-297 [PMID: 23500461 DOI: 10.1016/j.bbrc.2013.02.095]

41 **Zha M**, Xu W, Zhai Q, Li F, Chen B, Sun Z. High glucose aggravates the detrimental effects of pancreatic stellate cells on Beta-cell function. *Int J Endocrinol* 2014; **2014**: 165612 [PMID: 25097548 DOI: 10.1155/2014/165612]

42 **Li FF**, Chen BJ, Li W, Li L, Zha M, Zhou S, Bachem MG, Sun ZL. Islet Stellate Cells Isolated from Fibrotic Islet of Goto-Kakizaki Rats Affect Biological Behavior of Beta-Cell. *J Diabetes Res* 2016; **2016**: 6924593 [PMID: 26697502 DOI: 10.1155/2016/6924593]

43 **Zang G**, Sandberg M, Carlsson PO, Welsh N, Jansson L, Barbu A. Activated pancreatic stellate cells can impair pancreatic islet function in mice. *Ups J Med Sci* 2015; **120**: 169-180 [PMID: 25854824 DOI: 10.3109/03009734.2015.1032453]

44 **Li F**, Chen B, Li L, Zha M, Zhou S, Wu T, Bachem MG, Sun Z. INS-1 cells inhibit the production of extracellular matrix from pancreatic stellate cells. *J Mol Histol* 2014; **45**: 321-327 [PMID: 24202436 DOI: 10.1007/s10735-013-9547-y]

45 **Xu W**, Li W, Wang Y, Zha M, Yao H, Jones PM, Sun Z. Regenerating islet-derived protein 1 inhibits the activation of islet stellate cells isolated from diabetic mice. *Oncotarget* 2015; **6**: 37054-37065 [PMID: 26496027 DOI: 10.18632/oncotarget.6163]

46 **Fitzner B**, Müller S, Walther M, Fischer M, Engelmann R, Müller-Hilke B, Pützer BM, Kreutzer M, Nizze H, Jaster R. Senescence determines the fate of activated rat pancreatic stellate cells. *J Cell Mol Med* 2012; **16**: 2620-2630 [PMID: 22452900 DOI: 10.1111/j.1582-4934.2012.01573.x]

47 **Patel M**, Fine DR. Fibrogenesis in the pancreas after acinar cell injury. *Scand J Surg* 2005; **94**: 108-111 [PMID: 16111091 DOI: 10.1177/145749690509400205]

48 **Li N**, Li Y, Li Z, Huang C, Yang Y, Lang M, Cao J, Jiang W, Xu Y, Dong J, Ren H. Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. *Int J Mol Sci* 2016; **17**: [PMID: 27271610 DOI: 10.3390/ijms17060799]

49 **Vonlaufen A**, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, Toi CS, Pirola RC, Wilson JS, Goldstein D, Apte MV. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. *Cancer Res* 2008; **68**: 2085-2093 [PMID: 18381413 DOI: 10.1158/0008-5472.CAN-07-2477]

50 **Bachem MG**, Schünemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A, Adler G. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. *Gastroenterology* 2005; **128**: 907-921 [PMID: 15825074 DOI: 10.1053/j.gastro.2004.12.036]

51 **Apte MV**, Norton ID, Wilson JS. Ethanol induced acinar cell injury. *Alcohol Alcohol Suppl* 1994; **2**: 365-368 [PMID: 8974357]

52 **Haber PS**, Apte MV, Applegate TL, Norton ID, Korsten MA, Pirola RC, Wilson JS. Metabolism of ethanol by rat pancreatic acinar cells. *J Lab Clin Med* 1998; **132**: 294-302 [PMID: 9794700 DOI: 1]

53 **Wilson JS**, Apte MV. Role of alcohol metabolism in alcoholic pancreatitis. *Pancreas* 2003; **27**: 311-315 [PMID: 14576493 DOI: 10.1097/00006676-200311000-00007]

54 **Masamune A**, Kikuta K, Satoh M, Satoh A, Shimosegawa T. Alcohol activates activator protein-1 and mitogen-activated protein kinases in rat pancreatic stellate cells. *J Pharmacol Exp Ther* 2002; **302**: 36-42 [PMID: 12065697 DOI: 10.1124/jpet.302.1.36]

55 **Apte MV**, Pirola RC, Wilson JS. Battle-scarred pancreas: role of alcohol and pancreatic stellate cells in pancreatic fibrosis. *J Gastroenterol Hepatol* 2006; **21** Suppl 3: S97-S101 [PMID: 16958684 DOI: 10.1111/j.1440-1746.2006.04587.x]

56 **Casini A**, Galli A, Pignalosa P, Frulloni L, Grappone C, Milani S, Pederzoli P, Cavallini G, Surrenti C. Collagen type I synthesized by pancreatic periacinar stellate cells (PSC) co-localizes with lipid peroxidation-derived aldehydes in chronic alcoholic pancreatitis. *J Pathol* 2000; **192**: 81-89 [PMID: 10951404 DOI: 10.1002/1096-9896(2000)9999]

57 **Hu R**, Wang YL, Edderkaoui M, Lugea A, Apte MV, Pandol SJ. Ethanol augments PDGF-induced NADPH oxidase activity and proliferation in rat pancreatic stellate cells. *Pancreatology* 2007; **7**: 332-340 [PMID: 17627098 DOI: 10.1159/000105499]

58 **Gao R**, Brigstock DR. Connective tissue growth factor (CCN2) in rat pancreatic stellate cell function: integrin alpha5beta1 as a novel CCN2 receptor. *Gastroenterology* 2005; **129**: 1019-1030 [PMID: 16143139 DOI: 10.1053/j.gastro.2005.06.067]

59 **Charrier A**, Chen R, Chen L, Kemper S, Hattori T, Takigawa M, Brigstock DR. Connective tissue growth factor (CCN2) and microRNA-21 are components of a positive feedback loop in pancreatic stellate cells (PSC) during chronic pancreatitis and are exported in PSC-derived exosomes. *J Cell Commun Signal* 2014; **8**: 147-156 [PMID: 24464300 DOI: 10.1007/s12079-014-0220-3]

60 **Lee AT**, Xu Z, Pothula SP, Patel MB, Pirola RC, Wilson JS, Apte MV. Alcohol and cigarette smoke components activate human pancreatic stellate cells: implications for the progression of chronic pancreatitis. *Alcohol Clin Exp Res* 2015; **39**: 2123-2133 [PMID: 26463405 DOI: 10.1111/acer.12882]

61 **Tolstrup JS**, Kristiansen L, Becker U, Grønbaek M. Smoking and risk of acute and chronic pancreatitis among women and men: a population-based cohort study. *Arch Intern Med* 2009; **169**: 603-609 [PMID: 19307524 DOI: 10.1001/archinternmed.2008.601]

62 **Asaumi H**, Watanabe S, Taguchi M, Tashiro M, Otsuki M. Externally applied pressure activates pancreatic stellate cells through the generation of intracellular reactive oxygen species. *Am J Physiol Gastrointest Liver Physiol* 2007; **293**: G972-G978 [PMID: 17761838 DOI: 10.1152/ajpgi.00018.2007]

63 **Watanabe S**, Nagashio Y, Asaumi H, Nomiyama Y, Taguchi M, Tashiro M, Kihara Y, Nakamura H, Otsuki M. Pressure activates rat pancreatic stellate cells. *Am J Physiol Gastrointest Liver Physiol* 2004; **287**: G1175-G1181 [PMID: 15319186 DOI: 10.1152/ajpgi.00339.2004]

64 **Ko SH**, Hong OK, Kim JW, Ahn YB, Song KH, Cha BY, Son HY, Kim MJ, Jeong IK, Yoon KH. High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. *J Cell Biochem* 2006; **98**: 343-355 [PMID: 16408293 DOI: 10.1002/jcb.20797]

65 **Nomiyama Y**, Tashiro M, Yamaguchi T, Watanabe S, Taguchi M, Asaumi H, Nakamura H, Otsuki M. High glucose activates rat pancreatic stellate cells through protein kinase C and p38 mitogen-activated protein kinase pathway. *Pancreas* 2007; **34**: 364-372 [PMID: 17414061 DOI: 10.1097/MPA.0b013e31802f0531]

66 **Kiss K**, Baghy K, Spisák S, Szanyi S, Tulassay Z, Zalatnai A, Löhr JM, Jesenofsky R, Kovalszky I, Firneisz G. Chronic hyperglycemia induces trans-differentiation of human pancreatic stellate cells and enhances the malignant molecular communication with human pancreatic cancer cells. *PLoS One* 2015; **10**: e0128059 [PMID: 26010611 DOI: 10.1371/journal.pone.0128059]

67 **Apte MV**, Haber PS, Darby SJ, Rodgers SC, McCaughan GW, Korsten MA, Pirola RC, Wilson JS. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. *Gut* 1999; **44**: 534-541 [PMID: 10075961 DOI: 10.1136/gut.44.4.534]

68 **Tahara H**, Sato K, Yamazaki Y, Ohyama T, Horiguchi N, Hashizume H, Kakizaki S, Takagi H, Ozaki I, Arai H, Hirato J, Jesenofsky R, Masamune A, Mori M. Transforming growth factor-α activates pancreatic stellate cells and may be involved in matrix metalloproteinase-1 upregulation. *Lab Invest* 2013; **93**: 720-732 [PMID: 23608755 DOI: 10.1038/labinvest.2013.59]

69 **Andoh A**, Takaya H, Saotome T, Shimada M, Hata K, Araki Y, Nakamura F, Shintani Y, Fujiyama Y, Bamba T. Cytokine regulation of chemokine (IL-8, MCP-1, and RANTES) gene expression in human pancreatic periacinar myofibroblasts. *Gastroenterology* 2000; **119**: 211-219 [PMID: 10889171 DOI: 10.1053/gast.2000.8538]

70 **Ohnishi N**, Miyata T, Ohnishi H, Yasuda H, Tamada K, Ueda N, Mashima H, Sugano K. Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis. *Gut* 2003; **52**: 1487-1493 [PMID: 12970143 DOI: 10.1136/gut.52.10.1487]

71 **Hama K**, Ohnishi H, Aoki H, Kita H, Yamamoto H, Osawa H, Sato K, Tamada K, Mashima H, Yasuda H, Sugano K. Angiotensin II promotes the proliferation of activated pancreatic stellate cells by Smad7 induction through a protein kinase C pathway. *Biochem Biophys Res Commun* 2006; **340**: 742-750 [PMID: 16380081 DOI: 10.1016/j.bbrc.2005.12.069]

72 **Jaster R**, Sparmann G, Emmrich J, Liebe S. Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells. *Gut* 2002; **51**: 579-584 [PMID: 12235084 DOI: 10.1136/gut.51.4.579]

73 **Masamune A**, Kikuta K, Satoh M, Kume K, Shimosegawa T. Differential roles of signaling pathways for proliferation and migration of rat pancreatic stellate cells. *Tohoku J Exp Med* 2003; **199**: 69-84 [PMID: 12705352 DOI: 10.1620/tjem.199.69]

74 **Klonowski-Stumpe H**, Reinehr R, Fischer R, Warskulat U, Lüthen R, Häussinger D. Production and effects of endothelin-1 in rat pancreatic stellate cells. *Pancreas* 2003; **27**: 67-74 [PMID: 12826908 DOI: 10.1097/00006676-200307000-00010]

75 **Masamune A**, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Endothelin-1 stimulates contraction and migration of rat pancreatic stellate cells. *World J Gastroenterol* 2005; **11**: 6144-6151 [PMID: 16273641 DOI: 10.3748/wjg.v11.i39.6144]

76 **Uchida M**, Ito T, Nakamura T, Igarashi H, Oono T, Fujimori N, Kawabe K, Suzuki K, Jensen RT, Takayanagi R. ERK pathway and sheddases play an essential role in ethanol-induced CX3CL1 release in pancreatic stellate cells. *Lab Invest* 2013; **93**: 41-53 [PMID: 23147224 DOI: 10.1038/labinvest.2012.156]

77 **Uchida M**, Ito T, Nakamura T, Hijioka M, Igarashi H, Oono T, Kato M, Nakamura K, Suzuki K, Takayanagi R, Jensen RT. Pancreatic stellate cells and CX3CR1: occurrence in normal pancreas and acute and chronic pancreatitis and effect of their activation by a CX3CR1 agonist. *Pancreas* 2014; **43**: 708-719 [PMID: 24681877 DOI: 10.1097/MPA.0000000000000109]

78 **Lee YS**, Morinaga H, Kim JJ, Lagakos W, Taylor S, Keshwani M, Perkins G, Dong H, Kayali AG, Sweet IR, Olefsky J. The fractalkine/CX3CR1 system regulates β cell function and insulin secretion. *Cell* 2013; **153**: 413-425 [PMID: 23582329 DOI: 10.1016/j.cell.2013.03.001]

79 **Bhatia V**, Rastellini C, Han S, Aronson JF, Greeley GH, Falzon M. Acinar cell-specific knockout of the PTHrP gene decreases the proinflammatory and profibrotic responses in pancreatitis. *Am J Physiol Gastrointest Liver Physiol* 2014; **307**: G533-G549 [PMID: 25035110]

80 **Mews P**, Phillips P, Fahmy R, Korsten M, Pirola R, Wilson J, Apte M. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. *Gut* 2002; **50**: 535-541 [PMID: 11889076 DOI: 10.1136/gut.50.4.535]

81 **Xue J**, Sharma V, Hsieh MH, Chawla A, Murali R, Pandol SJ, Habtezion A. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. *Nat Commun* 2015; **6**: 7158 [PMID: 25981357 DOI: 10.1038/ncomms8158]

82 **Pearson G**, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocr Rev* 2001; **22**: 153-183 [PMID: 11294822 DOI: 10.1210/edrv.22.2.0428]

83 **Masamune A**, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Activation of JAK-STAT pathway is required for platelet-derived growth factor-induced proliferation of pancreatic stellate cells. *World J Gastroenterol* 2005; **11**: 3385-3391 [PMID: 15948243 DOI: 10.3748/wjg.v11.i22.3385]

84 **Nishida A**, Andoh A, Shioya M, Kim-Mitsuyama S, Takayanagi A, Fujiyama Y. Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-32alpha induction in human pancreatic periacinar myofibroblasts. *Am J Physiol Gastrointest Liver Physiol* 2008; **294**: G831-G838 [PMID: 18239058 DOI: 10.1152/ajpgi.00535]

85 **Masamune A**, Watanabe T, Kikuta K, Satoh K, Kanno A, Shimosegawa T. Nuclear expression of interleukin-33 in pancreatic stellate cells. *Am J Physiol Gastrointest Liver Physiol* 2010; **299**: G821-G832 [PMID: 20689058 DOI: 10.1152/ajpgi.00178.2010]

86 **Nishida A**, Andoh A, Imaeda H, Inatomi O, Shiomi H, Fujiyama Y. Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. *Gut* 2010; **59**: 531-541 [PMID: 19996325 DOI: 10.1136/gut.2009.193599]

87 **Kikuta K**, Masamune A, Satoh M, Suzuki N, Shimosegawa T. 4-hydroxy-2, 3-nonenal activates activator protein-1 and mitogen-activated protein kinases in rat pancreatic stellate cells. *World J Gastroenterol* 2004; **10**: 2344-2351 [PMID: 15285017 DOI: 10.3748/wjg.v10.i16.2344]

88 **McCarroll JA**, Phillips PA, Park S, Doherty E, Pirola RC, Wilson JS, Apte MV. Pancreatic stellate cell activation by ethanol and acetaldehyde: is it mediated by the mitogen-activated protein kinase signaling pathway? *Pancreas* 2003; **27**: 150-160 [PMID: 12883264 DOI: 10.1097/00006676-200308000-00008]

89 **Masamune A**, Kikuta K, Suzuki N, Satoh M, Satoh K, Shimosegawa T. A c-Jun NH2-terminal kinase inhibitor SP600125 (anthra[1,9-cd]pyrazole-6 (2H)-one) blocks activation of pancreatic stellate cells. *J Pharmacol Exp Ther* 2004; **310**: 520-527 [PMID: 15056726 DOI: 10.1124/jpet.104.067280]

90 **Shek FW**, Benyon RC, Walker FM, McCrudden PR, Pender SL, Williams EJ, Johnson PA, Johnson CD, Bateman AC, Fine DR, Iredale JP. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. *Am J Pathol* 2002; **160**: 1787-1798 [PMID: 12000730 DOI: 10.1016/S0002-9440(10)61125-X]

91 **Ohnishi H**, Miyata T, Yasuda H, Satoh Y, Hanatsuka K, Kita H, Ohashi A, Tamada K, Makita N, Iiri T, Ueda N, Mashima H, Sugano K. Distinct roles of Smad2-, Smad3-, and ERK-dependent pathways in transforming growth factor-beta1 regulation of pancreatic stellate cellular functions. *J Biol Chem* 2004; **279**: 8873-8878 [PMID: 14688282 DOI: 10.1074/jbc.M309698200]

92 **Aoki H**, Ohnishi H, Hama K, Ishijima T, Satoh Y, Hanatsuka K, Ohashi A, Wada S, Miyata T, Kita H, Yamamoto H, Osawa H, Sato K, Tamada K, Yasuda H, Mashima H, Sugano K. Autocrine loop between TGF-beta1 and IL-1beta through Smad3- and ERK-dependent pathways in rat pancreatic stellate cells. *Am J Physiol Cell Physiol* 2006; **290**: C1100-C1108 [PMID: 16371439 DOI: 10.1152/ajpcell.00465.2005]

93 **Aoki H**, Ohnishi H, Hama K, Shinozaki S, Kita H, Yamamoto H, Osawa H, Sato K, Tamada K, Sugano K. Existence of autocrine loop between interleukin-6 and transforming growth factor-beta1 in activated rat pancreatic stellate cells. *J Cell Biochem* 2006; **99**: 221-228 [PMID: 16598747 DOI: 10.1002/jcb.20906]

94 **Aoki H**, Ohnishi H, Hama K, Shinozaki S, Kita H, Osawa H, Yamamoto H, Sato K, Tamada K, Sugano K. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. *Am J Physiol Cell Physiol* 2007; **292**: C259-C268 [PMID: 16837651 DOI: 10.1152/ajpcell.00030.2006]

95 **Lee H**, Lim C, Lee J, Kim N, Bang S, Lee H, Min B, Park G, Noda M, Stetler-Stevenson WG, Oh J. TGF-beta signaling preserves RECK expression in activated pancreatic stellate cells. *J Cell Biochem* 2008; **104**: 1065-1074 [PMID: 18300271 DOI: 10.1002/jcb.21692]

96 **Hu Y**, Wan R, Yu G, Shen J, Ni J, Yin G, Xing M, Chen C, Fan Y, Xiao W, Xu G, Wang X, Hu G. Imbalance of Wnt/Dkk negative feedback promotes persistent activation of pancreatic stellate cells in chronic pancreatitis. *PLoS One* 2014; **9**: e95145 [PMID: 24747916 DOI: 10.1371/journal.pone.0095145]

97 **Xu Y**, Li H, Huang C, Zhao T, Zhang H, Zheng C, Ren H, Hao J. Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. *Med Oncol* 2015; **32**: 97 [PMID: 25731618 DOI: 10.1007/s12032-015-0513-2]

98 **Shinozaki S**, Ohnishi H, Hama K, Kita H, Yamamoto H, Osawa H, Sato K, Tamada K, Mashima H, Sugano K. Indian hedgehog promotes the migration of rat activated pancreatic stellate cells by increasing membrane type-1 matrix metalloproteinase on the plasma membrane. *J Cell Physiol* 2008; **216**: 38-46 [PMID: 18286538 DOI: 10.1002/jcp.21372]

99 **Bailey JM**, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA. Sonic hedgehog promotes desmoplasia in pancreatic cancer. *Clin Cancer Res* 2008; **14**: 5995-6004 [PMID: 18829478 DOI: 10.1158/1078-0432.CCR-08-0291]

100 **Li X**, Wang Z, Ma Q, Xu Q, Liu H, Duan W, Lei J, Ma J, Wang X, Lv S, Han L, Li W, Guo J, Guo K, Zhang D, Wu E, Xie K. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. *Clin Cancer Res* 2014; **20**: 4326-4338 [PMID: 24947933 DOI: 10.1158/1078-0432.CCR-13-3426]

101 **Han L**, Ma J, Duan W, Zhang L, Yu S, Xu Q, Lei J, Li X, Wang Z, Wu Z, Huang JH, Wu E, Ma Q, Ma Z. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway. *Oncotarget* 2016; **7**: 18146-18158 [PMID: 26934446 DOI: 10.18632/oncotarget.7776]

102 **Masamune A**, Nakano E, Hamada S, Takikawa T, Yoshida N, Shimosegawa T. Alteration of the microRNA expression profile during the activation of pancreatic stellate cells. *Scand J Gastroenterol* 2014; **49**: 323-331 [PMID: 24404812 DOI: 10.3109/00365521.2013.876447]

103 **Shen J**, Wan R, Hu G, Yang L, Xiong J, Wang F, Shen J, He S, Guo X, Ni J, Guo C, Wang X. miR-15b and miR-16 induce the apoptosis of rat activated pancreatic stellate cells by targeting Bcl-2 in vitro. *Pancreatology* 2012; **12**: 91-99 [PMID: 22487517 DOI: 10.1016/j.pan.2012.02.008]

104 **Aggarwal BB**. Nuclear factor-kappaB: the enemy within. *Cancer Cell* 2004; **6**: 203-208 [PMID: 15380510 DOI: 10.1016/j.ccr.2004.09.003]

105 **Masamune A**, Sakai Y, Kikuta K, Satoh M, Satoh A, Shimosegawa T. Activated rat pancreatic stellate cells express intercellular adhesion molecule-1 (ICAM-1) in vitro. *Pancreas* 2002; **25**: 78-85 [PMID: 12131776 DOI: 10.1097/00006676-200207000-00018]

106 **Shimada M**, Andoh A, Hata K, Tasaki K, Araki Y, Fujiyama Y, Bamba T. IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. *J Immunol* 2002; **168**: 861-868 [PMID: 11777983 DOI: 10.4049/jimmunol.168.2.861]

107 **Masamune A**, Kikuta K, Watanabe T, Satoh K, Satoh A, Shimosegawa T. Pancreatic stellate cells express Toll-like receptors. *J Gastroenterol* 2008; **43**: 352-362 [PMID: 18592153 DOI: 10.1007/s00535-008-2162-0]

108 **Masamune A**, Satoh M, Hirabayashi J, Kasai K, Satoh K, Shimosegawa T. Galectin-1 induces chemokine production and proliferation in pancreatic stellate cells. *Am J Physiol Gastrointest Liver Physiol* 2006; **290**: G729-G736 [PMID: 16373424 DOI: 10.1152/ajpgi.00511.2005]

109 **Paulo JA**, Urrutia R, Banks PA, Conwell DL, Steen H. Proteomic analysis of an immortalized mouse pancreatic stellate cell line identifies differentially-expressed proteins in activated vs nonproliferating cell states. *J Proteome Res* 2011; **10**: 4835-4844 [PMID: 21838295 DOI: 10.1021/pr2006318]

110 **Paulo JA**, Urrutia R, Banks PA, Conwell DL, Steen H. Proteomic analysis of a rat pancreatic stellate cell line using liquid chromatography tandem mass spectrometry (LC-MS/MS). *J Proteomics* 2011; **75**: 708-717 [PMID: 21968429 DOI: 10.1016/j.jprot.2011.09.009]

111 **Pan S**, Chen R, Stevens T, Bronner MP, May D, Tamura Y, McIntosh MW, Brentnall TA. Proteomics portrait of archival lesions of chronic pancreatitis. *PLoS One* 2011; **6**: e27574 [PMID: 22132114 DOI: 10.1371/journal.pone.0027574]

112 **Apte MV**, Yang L, Phillips PA, Xu Z, Kaplan W, Cowley M, Pirola RC, Wilson JS. Extracellular matrix composition significantly influences pancreatic stellate cell gene expression pattern: role of transgelin in PSC function. *Am J Physiol Gastrointest Liver Physiol* 2013; **305**: G408-G417 [PMID: 23868411 DOI: 10.1152/ajpgi.00016.2013]

113 **Paulo JA**, Kadiyala V, Banks PA, Conwell DL, Steen H. Mass spectrometry-based quantitative proteomic profiling of human pancreatic and hepatic stellate cell lines. *Genomics Proteomics Bioinformatics* 2013; **11**: 105-113 [PMID: 23528454 DOI: 10.1016/j.gpb.2013.01.009]

114 **Paulo JA**, Urrutia R, Kadiyala V, Banks P, Conwell DL, Steen H. Cross-species analysis of nicotine-induced proteomic alterations in pancreatic cells. *Proteomics* 2013; **13**: 1499-1512 [PMID: 23456891 DOI: 10.1002/pmic.201200492]

115 **Paulo JA**, Gaun A, Gygi SP. Global Analysis of Protein Expression and Phosphorylation Levels in Nicotine-Treated Pancreatic Stellate Cells. *J Proteome Res* 2015; **14**: 4246-4256 [PMID: 26265067 DOI: 10.1021/acs.jproteome.5b00398]

116 **Wehr AY**, Furth EE, Sangar V, Blair IA, Yu KH. Analysis of the human pancreatic stellate cell secreted proteome. *Pancreas* 2011; **40**: 557-566 [PMID: 21499210 DOI: 10.1097/MPA.0b013e318214efaf]

117 **Marzoq AJ**, Giese N, Hoheisel JD, Alhamdani MS. Proteome variations in pancreatic stellate cells upon stimulation with proinflammatory factors. *J Biol Chem* 2013; **288**: 32517-32527 [PMID: 24089530 DOI: 10.1074/jbc.M113.488387]

118 **Apte MV**, Xu Z, Pothula S, Goldstein D, Pirola RC, Wilson JS. Pancreatic cancer: The microenvironment needs attention too! *Pancreatology* 2015; **15**: S32-S38 [PMID: 25845856 DOI: 10.1016/j.pan.2015.02.013]

119 **Apte MV**, Wilson JS. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. *J Gastroenterol Hepatol* 2012; **27** Suppl 2: 69-74 [PMID: 22320920 DOI: 10.1111/j.1440-1746.2011.07000.x]

120 **Gore J**, Korc M. Pancreatic cancer stroma: friend or foe? *Cancer Cell* 2014; **25**: 711-712 [PMID: 24937454 DOI: 10.1016/j.ccr.2014.05.026]

121 **Vonlaufen A**, Phillips PA, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. *Cancer Res* 2008; **68**: 7707-7710 [PMID: 18829522 DOI: 10.1158/0008-5472.CAN-08-1132]

122 **Chang DZ**, Ma Y, Ji B, Wang H, Deng D, Liu Y, Abbruzzese JL, Liu YJ, Logsdon CD, Hwu P. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2011; **17**: 7015-7023 [PMID: 21976550 DOI: 10.1158/1078-0432.CCR-11-0607]

123 **Chang DZ**. Mast cells in pancreatic ductal adenocarcinoma. *Oncoimmunology* 2012; **1**: 754-755 [PMID: 22934272 DOI: 10.4161/onci.19612]

124 **Ma Y**, Hwang RF, Logsdon CD, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. *Cancer Res* 2013; **73**: 3927-3937 [PMID: 23633481 DOI: 10.1158/0008-5472.CAN-12-4479]

125 **Pandol SJ**, Edderkaoui M. What are the macrophages and stellate cells doing in pancreatic adenocarcinoma? *Front Physiol* 2015; **6**: 125 [PMID: 26029109 DOI: 10.3389/fphys.2015.00125]

126 **Hu H**, Jiao F, Han T, Wang LW. Functional significance of macrophages in pancreatic cancer biology. *Tumour Biol* 2015; **36**: 9119-9126 [PMID: 26411672 DOI: 10.1007/s13277-015-4127-2]

127 **Tewari N**, Zaitoun AM, Arora A, Madhusudan S, Ilyas M, Lobo DN. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. *BMC Cancer* 2013; **13**: 436 [PMID: 24063854 DOI: 10.1186/1471-2407-13-436]

128 **Stromnes IM**, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. *Gut* 2014; **63**: 1769-1781 [PMID: 24555999 DOI: 10.1136/gutjnl-2013-306271]

129 **Xu XD**, Hu J, Wang M, Peng F, Tian R, Guo XJ, Xie Y, Qin RY. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. *Hepatobiliary Pancreat Dis Int* 2016; **15**: 99-105 [PMID: 26818550 DOI: 10.1016/S1499-3872(15)60413-1]

130 **Korc M**. Pancreatic cancer-associated stroma production. *Am J Surg* 2007; **194**: S84-S86 [PMID: 17903452]

131 **Maity G**, Mehta S, Haque I, Dhar K, Sarkar S, Banerjee SK, Banerjee S. Pancreatic tumor cell secreted CCN1/Cyr61 promotes endothelial cell migration and aberrant neovascularization. *Sci Rep* 2014; **4**: 4995 [PMID: 24833309 DOI: 10.1038/srep04995]

132 **Lunardi S**, Muschel RJ, Brunner TB. The stromal compartments in pancreatic cancer: are there any therapeutic targets? *Cancer Lett* 2014; **343**: 147-155 [PMID: 24141189 DOI: 10.1016/j.canlet.2013.09.039]

133 **Pothula SP**, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Key role of pancreatic stellate cells in pancreatic cancer. *Cancer Lett* 2016; **381**: 194-200 [PMID: 26571462 DOI: 10.1016/j.canlet.2015.10.035]

134 **Patel MB**, Pothula SP, Xu Z, Lee AK, Goldstein D, Pirola RC, Apte MV, Wilson JS. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. *Carcinogenesis* 2014; **35**: 1891-1900 [PMID: 24876152 DOI: 10.1093/carcin/bgu122]

135 **Pothula SP**, Xu Z, Goldstein D, Biankin AV, Pirola RC, Wilson JS, Apte MV. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. *Br J Cancer* 2016; **114**: 269-280 [PMID: 26766740 DOI: 10.1038/bjc.2015.478]

136 **Hwang RF**, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. *Cancer Res* 2008; **68**: 918-926 [PMID: 18245495 DOI: 10.1158/0008-5472.CAN-07-5714]

137 **Kikuta K**, Masamune A, Watanabe T, Ariga H, Itoh H, Hamada S, Satoh K, Egawa S, Unno M, Shimosegawa T. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. *Biochem Biophys Res Commun* 2010; **403**: 380-384 [PMID: 21081113 DOI: 10.1016/j.bbrc.2010.11.040]

138 **Fujiwara K**, Ohuchida K, Ohtsuka T, Mizumoto K, Shindo K, Ikenaga N, Cui L, Takahata S, Aishima S, Tanaka M. Migratory activity of CD105+ pancreatic cancer cells is strongly enhanced by pancreatic stellate cells. *Pancreas* 2013; **42**: 1283-1290 [PMID: 24308064 DOI: 10.1097/MPA.0b013e318293e7bd]

139 **Hamada S**, Masamune A, Takikawa T, Suzuki N, Kikuta K, Hirota M, Hamada H, Kobune M, Satoh K, Shimosegawa T. Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. *Biochem Biophys Res Commun* 2012; **421**: 349-354 [PMID: 22510406 DOI: 10.1016/j.bbrc.2012.04.014]

140 **Ikenaga N**, Ohuchida K, Mizumoto K, Cui L, Kayashima T, Morimatsu K, Moriyama T, Nakata K, Fujita H, Tanaka M. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. *Gastroenterology* 2010; **139**: 1041-151, 1041-151, [PMID: 20685603 DOI: 10.1053/j.gastro.2010.05.084]

141 **Arumugam T**, Brandt W, Ramachandran V, Moore TT, Wang H, May FE, Westley BR, Hwang RF, Logsdon CD. Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis. *Pancreas* 2011; **40**: 815-822 [PMID: 21747314 DOI: 10.1097/MPA.0b013e31821f6927]

142 **Koshiba T**, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R, Imamura M. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. *Int J Pancreatol* 1999; **26**: 69-76 [PMID: 10597402 DOI: 10.1007/BF02781733]

143 **Tucker ON**, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. *Cancer Res* 1999; **59**: 987-990 [PMID: 10070951]

144 **Kokawa A**, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, Yoshida S. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. *Cancer* 2001; **91**: 333-338 [PMID: 11180079 DOI: 10.1002/1097-0142(20010115)91]

145 **Merati K**, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. *Am J Clin Oncol* 2001; **24**: 447-452 [PMID: 11586094 DOI: 10.1097/00000421-200110000-00007]

146 **Jiang HB**, Xu M, Wang XP. Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3. *World J Gastroenterol* 2008; **14**: 2023-2028 [PMID: 18395901 DOI: 10.3748/wjg.14.2023]

147 **Tang D**, Yuan Z, Xue X, Lu Z, Zhang Y, Wang H, Chen M, An Y, Wei J, Zhu Y, Miao Y, Jiang K. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. *Int J Cancer* 2012; **130**: 2337-2348 [PMID: 21780106 DOI: 10.1002/ijc.26290]

148 **Farrow B**, Berger DH, Rowley D. Tumor-derived pancreatic stellate cells promote pancreatic cancer cell invasion through release of thrombospondin-2. *J Surg Res* 2009; **156**: 155-160 [PMID: 19592030 DOI: 10.1016/j.jss.2009.03.040]

149 **Gao Z**, Wang X, Wu K, Zhao Y, Hu G. Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis. *Pancreatology* 2010; **10**: 186-193 [PMID: 20484957 DOI: 10.1159/000236012]

150 **Zhou Y**, Zhou Q, Chen R. Pancreatic stellate cells promotes the perineural invasion in pancreatic cancer. *Med Hypotheses* 2012; **78**: 811-813 [PMID: 22513235 DOI: 10.1016/j.mehy.2012.03.017]

151 **Buchholz M**, Biebl A, Neesse A, Wagner M, Iwamura T, Leder G, Adler G, Gress TM. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. *Cancer Res* 2003; **63**: 4945-4951 [PMID: 12941819]

152 **Neesse A**, Wagner M, Ellenrieder V, Bachem M, Gress TM, Buchholz M. Pancreatic stellate cells potentiate proinvasive effects of SERPINE2 expression in pancreatic cancer xenograft tumors. *Pancreatology* 2007; **7**: 380-385 [PMID: 17703087 DOI: 10.1159/000107400]

153 **Tian X**, Chen G, Zhou S, Henne-Bruns D, Bachem M, Kornmann M. Interactions of pancreatic cancer and stellate cells are mediated by FGFR1-III isoform expression. *Hepatogastroenterology* ; **59**: 1604-1608 [PMID: 22683979 DOI: 10.5754/hge10366]

154 **Coleman SJ**, Chioni AM, Ghallab M, Anderson RK, Lemoine NR, Kocher HM, Grose RP. Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. *EMBO Mol Med* 2014; **6**: 467-481 [PMID: 24503018 DOI: 10.1002/emmm.201302698]

155 **Xu Z**, Vonlaufen A, Phillips PA, Fiala-Beer E, Zhang X, Yang L, Biankin AV, Goldstein D, Pirola RC, Wilson JS, Apte MV. Role of pancreatic stellate cells in pancreatic cancer metastasis. *Am J Pathol* 2010; **177**: 2585-2596 [PMID: 20934972 DOI: 10.2353/ajpath.2010.090899]

156 **Rebours V**, Albuquerque M, Sauvanet A, Ruszniewski P, Lévy P, Paradis V, Bedossa P, Couvelard A. Hypoxia pathways and cellular stress activate pancreatic stellate cells: development of an organotypic culture model of thick slices of normal human pancreas. *PLoS One* 2013; **8**: e76229 [PMID: 24098783 DOI: 10.1371/journal.pone.0076229]

157 **Masamune A**, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. *Am J Physiol Gastrointest Liver Physiol* 2008; **295**: G709-G717 [PMID: 18669622 DOI: 10.1152/ajpgi.90356.2008]

158 **Erkan M**, Reiser-Erkan C, Michalski CW, Deucker S, Sauliunaite D, Streit S, Esposito I, Friess H, Kleeff J. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. *Neoplasia* 2009; **11**: 497-508 [PMID: 19412434 DOI: 10.1593/neo.81618]

159 **Sada M**, Ohuchida K, Horioka K, Okumura T, Moriyama T, Miyasaka Y, Ohtsuka T, Mizumoto K, Oda Y, Nakamura M. Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. *Cancer Lett* 2016; **372**: 210-218 [PMID: 26805763 DOI: 10.1016/j.canlet.2016.01.016]

160 **Erkan M**, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA, Friess H. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. *Gastroenterology* 2007; **132**: 1447-1464 [PMID: 17408641 DOI: 10.1053/j.gastro.2007.01.031]

161 **Takikawa T**, Masamune A, Hamada S, Nakano E, Yoshida N, Shimosegawa T. miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. *Biochem Biophys Res Commun* 2013; **437**: 433-439 [PMID: 23831622 DOI: 10.1016/j.bbrc.2013.06.097]

162 **Kadera BE**, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. *PLoS One* 2013; **8**: e71978 [PMID: 23991015 DOI: 10.1371/journal.pone.0071978]

163 **Kuninty PR**, Bojmar L, Tjomsland V, Larsson M, Storm G, Östman A, Sandström P, Prakash J. MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. *Oncotarget* 2016; **7**: 16396-16408 [PMID: 26918939 DOI: 10.18632/oncotarget.7651]

164 **Kwon JJ**, Nabinger SC, Vega Z, Sahu SS, Alluri RK, Abdul-Sater Z, Yu Z, Gore J, Nalepa G, Saxena R, Korc M, Kota J. Pathophysiological role of microRNA-29 in pancreatic cancer stroma. *Sci Rep* 2015; **5**: 11450 [PMID: 26095125 DOI: 10.1038/srep11450]

165 **Ene-Obong A**, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J, Chelala C, Gribben JG, Ramsay AG, Kocher HM. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. *Gastroenterology* 2013; **145**: 1121-1132 [PMID: 23891972 DOI: 10.1053/j.gastro.2013.07.025]

166 **Tang D**, Gao J, Wang S, Yuan Z, Ye N, Chong Y, Xu C, Jiang X, Li B, Yin W, Miao Y, Wang D, Jiang K. Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. *Tumour Biol* 2015; **36**: 5617-5626 [PMID: 25725585 DOI: 10.1007/s13277-015-3233-5]

167 **Shi C**, Washington MK, Chaturvedi R, Drosos Y, Revetta FL, Weaver CJ, Buzhardt E, Yull FE, Blackwell TS, Sosa-Pineda B, Whitehead RH, Beauchamp RD, Wilson KT, Means AL. Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction. *Lab Invest* 2014; **94**: 409-421 [PMID: 24535260]

168 **Kraman M**, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. *Science* 2010; **330**: 827-830 [PMID: 21051638 DOI: 10.1126/science.1195300]

169 **Nakamura F**, Shintani Y, Saotome T, Fujiyama Y, Bamba T. Effects of synthetic serine protease inhibitors on proliferation and collagen synthesis of human pancreatic periacinar fibroblast-like cells. *Pancreas* 2001; **22**: 317-325 [PMID: 11291936 DOI: 10.1097/00006676-200104000-00015]

170 **Xie MJ**, Motoo Y, Su SB, Iovanna JL, Sawabu N. Effect of carboxamide derivative IS-741 on rat spontaneous chronic pancreatitis. *Dig Dis Sci* 2002; **47**: 139-147 [PMID: 11837714 DOI: 10.1023/A: 1013232024148]

171 **Kuno A**, Yamada T, Masuda K, Ogawa K, Sogawa M, Nakamura S, Nakazawa T, Ohara H, Nomura T, Joh T, Shirai T, Itoh M. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. *Gastroenterology* 2003; **124**: 1010-1019 [PMID: 12671898 DOI: 10.1053/gast.2003.50147]

172 **Yamada T**, Kuno A, Masuda K, Ogawa K, Sogawa M, Nakamura S, Ando T, Sano H, Nakazawa T, Ohara H, Nomura T, Joh T, Itoh M. Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. *J Pharmacol Exp Ther* 2003; **307**: 17-23 [PMID: 12944495 DOI: 10.1124/jpet.103.053322]

173 **Masamune A**, Kikuta K, Satoh M, Satoh K, Shimosegawa T. Rho kinase inhibitors block activation of pancreatic stellate cells. *Br J Pharmacol* 2003; **140**: 1292-1302 [PMID: 14581180 DOI: 10.1038/sj.bjp.0705551]

174 **Nagashio Y**, Ueno H, Imamura M, Asaumi H, Watanabe S, Yamaguchi T, Taguchi M, Tashiro M, Otsuki M. Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice. *Lab Invest* 2004; **84**: 1610-1618 [PMID: 15502860 DOI: 10.1038/labinvest.3700191]

175 **Zhao HF**, Ito T, Gibo J, Kawabe K, Oono T, Kaku T, Arita Y, Zhao QW, Usui M, Egashira K, Nawata H. Anti-monocyte chemoattractant protein 1 gene therapy attenuates experimental chronic pancreatitis induced by dibutyltin dichloride in rats. *Gut* 2005; **54**: 1759-1767 [PMID: 16284287 DOI: 10.1136/gut.2004.049403]

176 **Gibo J**, Ito T, Kawabe K, Hisano T, Inoue M, Fujimori N, Oono T, Arita Y, Nawata H. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. *Lab Invest* 2005; **85**: 75-89 [PMID: 15531908 DOI: 10.1038/labinvest.3700203]

177 **Yamada T**, Kuno A, Ogawa K, Tang M, Masuda K, Nakamura S, Ando T, Okamoto T, Ohara H, Nomura T, Joh T, Shirai T, Itoh M. Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. *J Pharmacol Exp Ther* 2005; **313**: 36-45 [PMID: 15608084 DOI: 10.1124/jpet.104.077883]

178 **van Westerloo DJ**, Florquin S, de Boer AM, Daalhuisen J, de Vos AF, Bruno MJ, van der Poll T. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. *Am J Pathol* 2005; **166**: 721-728 [PMID: 15743784 DOI: 10.1016/S0002-9440(10)62293-6]

179 **Reding T**, Bimmler D, Perren A, Sun LK, Fortunato F, Storni F, Graf R. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. *Gut* 2006; **55**: 1165-1173 [PMID: 16322109 DOI: 10.1136/gut.2005.077925]

180 **Asaumi H**, Watanabe S, Taguchi M, Tashiro M, Nagashio Y, Nomiyama Y, Nakamura H, Otsuki M. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits ethanol-induced activation of pancreatic stellate cells. *Eur J Clin Invest* 2006; **36**: 113-122 [PMID: 16436093 DOI: 10.1111/j.1365-2362.2006.01599.x]

181 **Baumert JT**, Sparmann G, Emmrich J, Liebe S, Jaster R. Inhibitory effects of interferons on pancreatic stellate cell activation. *World J Gastroenterol* 2006; **12**: 896-901 [PMID: 16521217 DOI: 10.3748/wjg.v12.i6.896]

182 **Fitzner B**, Brock P, Nechutova H, Glass A, Karopka T, Koczan D, Thiesen HJ, Sparmann G, Emmrich J, Liebe S, Jaster R. Inhibitory effects of interferon-gamma on activation of rat pancreatic stellate cells are mediated by STAT1 and involve down-regulation of CTGF expression. *Cell Signal* 2007; **19**: 782-790 [PMID: 17116388 DOI: 10.1016/j.cellsig.2006.10.002]

183 **Ohashi S**, Nishio A, Nakamura H, Asada M, Tamaki H, Kawasaki K, Fukui T, Yodoi J, Chiba T. Overexpression of redox-active protein thioredoxin-1 prevents development of chronic pancreatitis in mice. *Antioxid Redox Signal* 2006; **8**: 1835-1845 [PMID: 16987036 DOI: 10.1089/ars.2006.8.1835]

184 **McCarroll JA**, Phillips PA, Santucci N, Pirola RC, Wilson JS, Apte MV. Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis. *Gut* 2006; **55**: 79-89 [PMID: 16043492 DOI: 10.1136/gut.2005.064543]

185 **Tasci I**, Deveci S, Isik AT, Comert B, Akay C, Mas N, Inal V, Yamanel L, Mas MR. Allopurinol in rat chronic pancreatitis: effects on pancreatic stellate cell activation. *Pancreas* 2007; **35**: 366-371 [PMID: 18090245 DOI: 10.1097/mpa.0b013e31806dbaaa]

186 **Lu XL**, Song YH, Fu YB, Si JM, Qian KD. Ascorbic acid alleviates pancreatic damage induced by dibutyltin dichloride (DBTC) in rats. *Yonsei Med J* 2007; **48**: 1028-1034 [PMID: 18159597 DOI: 10.3349/ymj.2007.48.6.1028]

187 **Shirahige A**, Mizushima T, Matsushita K, Sawa K, Ochi K, Ichimura M, Tanioka H, Shinji T, Koide N, Tanimoto M. Oral administration of taurine improves experimental pancreatic fibrosis. *J Gastroenterol Hepatol* 2008; **23**: 321-327 [PMID: 17764527 DOI: 10.1111/j.1440-1746.2007.05127.x]

188 **Rickmann M**, Vaquero EC, Malagelada JR, Molero X. Tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway. *Gastroenterology* 2007; **132**: 2518-2532 [PMID: 17570223]

189 **Michalski CW**, Maier M, Erkan M, Sauliunaite D, Bergmann F, Pacher P, Batkai S, Giese NA, Giese T, Friess H, Kleeff J. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. *PLoS One* 2008; **3**: e1701 [PMID: 18301776 DOI: 10.1371/journal.pone.0001701]

190 **Weylandt KH**, Nadolny A, Kahlke L, Köhnke T, Schmöcker C, Wang J, Lauwers GY, Glickman JN, Kang JX. Reduction of inflammation and chronic tissue damage by omega-3 fatty acids in fat-1 transgenic mice with pancreatitis. *Biochim Biophys Acta* 2008; **1782**: 634-641 [PMID: 18832028 DOI: 10.1016/j.bbadis.2008.08.011]

191 **Karatas A**, Paksoy M, Erzin Y, Carkman S, Gonenc M, Ayan F, Aydogan F, Uzun H, Durak H. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of pancreatic fibrosis in an experimental model of severe hyperstimulation and obstruction pancreatitis. *J Surg Res* 2008; **148**: 7-12 [PMID: 18570924 DOI: 10.1016/j.jss.2008.03.015]

192 **Fitzner B**, Brock P, Holzhüter SA, Nizze H, Sparmann G, Emmrich J, Liebe S, Jaster R. Synergistic growth inhibitory effects of the dual endothelin-1 receptor antagonist bosentan on pancreatic stellate and cancer cells. *Dig Dis Sci* 2009; **54**: 309-320 [PMID: 18612819 DOI: 10.1007/s10620-008-0366-z]

193 **Schwer CI**, Mutschler M, Stoll P, Goebel U, Humar M, Hoetzel A, Schmidt R. Carbon monoxide releasing molecule-2 inhibits pancreatic stellate cell proliferation by activating p38 mitogen-activated protein kinase/heme oxygenase-1 signaling. *Mol Pharmacol* 2010; **77**: 660-669 [PMID: 20053955 DOI: 10.1124/mol.109.059519]

194 **Nathan JD**, Romac J, Peng RY, Peyton M, Rockey DC, Liddle RA. Protection against chronic pancreatitis and pancreatic fibrosis in mice overexpressing pancreatic secretory trypsin inhibitor. *Pancreas* 2010; **39**: e24-e30 [PMID: 19904222 DOI: 10.1097/MPA.0b013e3181bc45e9]

195 **González AM**, Garcia T, Samper E, Rickmann M, Vaquero EC, Molero X. Assessment of the protective effects of oral tocotrienols in arginine chronic-like pancreatitis. *Am J Physiol Gastrointest Liver Physiol* 2011; **301**: G846-G855 [PMID: 21852363 DOI: 10.1152/ajpgi.00485.2010]

196 **Long D**, Lu J, Luo L, Guo Y, Li C, Wu W, Shan J, Li L, Li S, Li Y, Lin T, Feng L. Effects of octreotide on activated pancreatic stellate cell-induced pancreas graft fibrosis in rats. *J Surg Res* 2012; **176**: 248-259 [PMID: 21816420 DOI: 10.1016/j.jss.2011.06.009]

194 **Li L**, Bimmler D, Graf R, Zhou S, Sun Z, Chen J, Siech M, Bachem MG. PSP/reg inhibits cultured pancreatic stellate cell and regulates MMP/ TIMP ratio. *Eur J Clin Invest* 2011; **41**: 151-158 [PMID: 20860757 DOI: 10.1111/j.1365-2362.2010.02390.x]

198 **Tang Y**, Liao Y, Kawaguchi-Sakita N, Raut V, Fakhrejahani E, Qian N, Toi M. Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats. *J Hepatobiliary Pancreat Sci* 2011; **18**: 551-558 [PMID: 21234610 DOI: 10.1007/s00534-010-0368-z]

199 **Wei L**, Yamamoto M, Harada M, Otsuki M. Treatment with pravastatin attenuates progression of chronic pancreatitis in rat. *Lab Invest* 2011; **91**: 872-884 [PMID: 21383674 DOI: 10.1038/labinvest.2011.41]

200 **Li XC**, Lu XL, Chen HH. α-Tocopherol treatment ameliorates chronic pancreatitis in an experimental rat model induced by trinitrobenzene sulfonic acid. *Pancreatology* 2011; **11**: 5-11 [PMID: 21311207 DOI: 10.1159/000309252]

201 **Monteiro TH**, Silva CS, Cordeiro Simões Ambrosio LM, Zucoloto S, Vannucchi H. Vitamin E alters inflammatory gene expression in alcoholic chronic pancreatitis. *J Nutrigenet Nutrigenomics* 2012; **5**: 94-105 [PMID: 22890014 DOI: 10.1159/000336076]

202 **Matsushita K**, Mizushima T, Shirahige A, Tanioka H, Sawa K, Ochi K, Tanimoto M, Koide N. Effect of taurine on acinar cell apoptosis and pancreatic fibrosis in dibutyltin dichloride-induced chronic pancreatitis. *Acta Med Okayama* 2012; **66**: 329-334 [PMID: 22918205]

203 **Yang L**, Shen J, He S, Hu G, Shen J, Wang F, Xu L, Dai W, Xiong J, Ni J, Guo C, Wan R, Wang X. L-cysteine administration attenuates pancreatic fibrosis induced by TNBS in rats by inhibiting the activation of pancreatic stellate cell. *PLoS One* 2012; **7**: e31807 [PMID: 22359633 DOI: 10.1371/journal.pone.0031807]

204 **Bai H**, Chen X, Zhang L, Dou X. The effect of sulindac, a non-steroidal anti-inflammatory drug, attenuates inflammation and fibrosis in a mouse model of chronic pancreatitis. *BMC Gastroenterol* 2012; **12**: 115 [PMID: 22920325 DOI: 10.1186/1471-230X-12-115]

205 **Lee BJ**, Lee HS, Kim CD, Jung SW, Seo YS, Kim YS, Jeen YT, Chun HJ, Um SH, Lee SW, Choi JH, Ryu HS. The Effects of Combined Treatment with an HMG-CoA Reductase Inhibitor and PPARγ Agonist on the Activation of Rat Pancreatic Stellate Cells. *Gut Liver* 2012; **6**: 262-269 [PMID: 22570758 DOI: 10.5009/gnl.2012.6.2.262]

206 **Shen J**, Gao J, Chen C, Lu H, Hu G, Shen J, Zhu S, Wu M, Wang X, Qian L, Yu Y, Han W, Wan R, Wang X. Antifibrotic role of chemokine CXCL9 in experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats. *Cytokine* 2013; **64**: 382-394 [PMID: 23819906 DOI: 10.1016/j.cyto.2013.05.012]

207 **Gao X**, Cao Y, Yang W, Duan C, Aronson JF, Rastellini C, Chao C, Hellmich MR, Ko TC. BMP2 inhibits TGF-β-induced pancreatic stellate cell activation and extracellular matrix formation. *Am J Physiol Gastrointest Liver Physiol* 2013; **304**: G804-G813 [PMID: 23429583 DOI: 10.1152/ajpgi.00306.2012]

208 **Zhou CH**, Lin-Li XY, Wen-Tang DM, Dong Y, Li LY, Wang SF. Protective effects of edaravone on experimental chronic pancreatitis induced by dibutyltin dichloride in rats. *Pancreatology* ; **13**: 125-132 [PMID: 23561970 DOI: 10.1016/j.pan.2013.01.007]

209 **Niina Y**, Ito T, Oono T, Nakamura T, Fujimori N, Igarashi H, Sakai Y, Takayanagi R. A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats. *Pancreatology* ; **14**: 201-210 [PMID: 24854616 DOI: 10.1016/j.pan.2014.02.009]

210 **Mrazek AA**, Porro LJ, Bhatia V, Falzon M, Spratt H, Zhou J, Chao C, Hellmich MR. Apigenin inhibits pancreatic stellate cell activity in pancreatitis. *J Surg Res* 2015; **196**: 8-16 [PMID: 25799526 DOI: 10.1016/j.jss.2015.02.032]

211 **Tsang SW**, Zhang H, Lin Z, Mu H, Bian ZX. Anti-fibrotic effect of trans-resveratrol on pancreatic stellate cells. *Biomed Pharmacother* 2015; **71**: 91-97 [PMID: 25960221 DOI: 10.1016/j.biopha.2015.02.013]

212 **Lin Z**, Zheng LC, Zhang HJ, Tsang SW, Bian ZX. Anti-fibrotic effects of phenolic compounds on pancreatic stellate cells. *BMC Complement Altern Med* 2015; **15**: 259 [PMID: 26223780 DOI: 10.1186/s12906-015-0789-y]

213 **Gundewar C**, Ansari D, Tang L, Wang Y, Liang G, Rosendahl AH, Saleem MA, Andersson R. Antiproliferative effects of curcumin analog L49H37 in pancreatic stellate cells: a comparative study. *Ann Gastroenterol* ; **28**: 391-398 [PMID: 26129848]

214 **Tsang SW**, Zhang HJ, Chen YG, Auyeung KK, Bian ZX. Eruberin A, a Natural Flavanol Glycoside, Exerts Anti-Fibrotic Action on Pancreatic Stellate Cells. *Cell Physiol Biochem* 2015; **36**: 2433-2446 [PMID: 26279445 DOI: 10.1159/000430204]

215 **Bläuer M**, Sand J, Laukkarinen J. Physiological and clinically attainable concentrations of 1,25-dihydroxyvitamin D3 suppress proliferation and extracellular matrix protein expression in mouse pancreatic stellate cells. *Pancreatology* ; **15**: 366-371 [PMID: 26005021 DOI: 10.1016/j.pan.2015.05.044]

216 **Xiao W**, Jiang W, Shen J, Yin G, Fan Y, Wu D, Qiu L, Yu G, Xing M, Hu G, Wang X, Wan R. Retinoic Acid Ameliorates Pancreatic Fibrosis and Inhibits the Activation of Pancreatic Stellate Cells in Mice with Experimental Chronic Pancreatitis via Suppressing the Wnt/β-Catenin Signaling Pathway. *PLoS One* 2015; **10**: e0141462 [PMID: 26556479 DOI: 10.1371/journal.pone.0141462]

217 **Witteck L**, Jaster R. Trametinib and dactolisib but not regorafenib exert antiproliferative effects on rat pancreatic stellate cells. *Hepatobiliary Pancreat Dis Int* 2015; **14**: 642-650 [PMID: 26663013 DOI: 10.1016/S1499-3872(15)60032-7]

218 **Ulmasov B**, Neuschwander-Tetri BA, Lai J, Monastyrskiy V, Trisha Bhat, Yates MP, Oliva J, Prinsen MJ, Ruminski PG, Griggs DW. Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice. *Cell Mol Gastroenterol Hepatol* 2016; **2**: 499–518 [DOI: 10.1016/j.jcmgh.2016.03.004]

219 **Feldmann G**, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, Gabrielson KL, Matsui W, Maitra A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. *Cancer Res* 2007; **67**: 2187-2196 [PMID: 17332349 DOI: 10.1158/0008-5472.CAN-06-3281]

220 **Diep CH**, Munoz RM, Choudhary A, Von Hoff DD, Han H. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. *Clin Cancer Res* 2011; **17**: 2744-2756 [PMID: 21385921 DOI: 10.1158/1078-0432.CCR-10-2214]

221 **Froeling FE**, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. *Gastroenterology* 2011; **141**: 1486-197, 1486-197, [PMID: 21704588 DOI: 10.1053/j.gastro.2011.06.047]

222 **Chauhan VP**, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, Popović Z, Huang P, Bawendi MG, Boucher Y, Jain RK. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. *Nat Commun* 2013; **4**: 2516 [PMID: 24084631 DOI: 10.1038/ncomms3516]

223 **Sun XD**, Liu XE, Huang DS. Curcumin reverses the epithelial-mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathway. *Oncol Rep* 2013; **29**: 2401-2407 [PMID: 23563640 DOI: 10.3892/or.2013.2385]

224 **Edderkaoui M**, Lugea A, Hui H, Eibl G, Lu QY, Moro A, Lu X, Li G, Go VL, Pandol SJ. Ellagic acid and embelin affect key cellular components of pancreatic adenocarcinoma, cancer, and stellate cells. *Nutr Cancer* 2013; **65**: 1232-1244 [PMID: 24127740 DOI: 10.1080/01635581.2013.832779]

225 **Macha MA**, Rachagani S, Gupta S, Pai P, Ponnusamy MP, Batra SK, Jain M. Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. *Cancer Lett* 2013; **341**: 166-177 [PMID: 23920124 DOI: 10.1016/j.canlet.2013.07.037]

226 **Kozono S**, Ohuchida K, Eguchi D, Ikenaga N, Fujiwara K, Cui L, Mizumoto K, Tanaka M. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. *Cancer Res* 2013; **73**: 2345-2356 [PMID: 23348422 DOI: 10.1158/0008-5472.CAN-12-3180]

227 **Guan J**, Zhang H, Wen Z, Gu Y, Cheng Y, Sun Y, Zhang T, Jia C, Lu Z, Chen J. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. *Cancer Lett* 2014; **345**: 132-139 [PMID: 24334138 DOI: 10.1016/j.canlet.2013.12.006]

228 **Gonzalez-Villasana V**, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. *Mol Cancer Ther* 2014; **13**: 2583-2594 [PMID: 25193509 DOI: 10.1158/1535-7163]

229 **Pomianowska E**, Sandnes D, Grzyb K, Schjølberg AR, Aasrum M, Tveteraas IH, Tjomsland V, Christoffersen T, Gladhaug IP. Inhibitory effects of prostaglandin E2 on collagen synthesis and cell proliferation in human stellate cells from pancreatic head adenocarcinoma. *BMC Cancer* 2014; **14**: 413 [PMID: 24912820 DOI: 10.1186/1471-2407-14-413]

230 **Gong J**, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, Reddick R, Kopetz S, Peterson A, Wang H, Fischer SM, Kumar AP. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. *Clin Cancer Res* 2014; **20**: 1259-1273 [PMID: 24520096 DOI: 10.1158/1078-0432.CCR-13-1664]

231 **Yan HH,** Jung KH, Son MK, Fang Z, Kim SJ, Ryu YL, Kim J, Kim MH, Hong SS. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. *Oncotarget* 2014; **5**: 9150-9168 [PMID: 25193856 DOI: 10.18632/oncotarget.2363]

232 **Zhang H**, Zhou WC, Li X, Meng WB, Zhang L, Zhu XL, Zhu KX, Bai ZT, Yan J, Liu T, Xu XC, Li YM. 5-Azacytidine suppresses the proliferation of pancreatic cancer cells by inhibiting the Wnt/β-catenin signaling pathway. *Genet Mol Res* 2014; **13**: 5064-5072 [PMID: 25061731 DOI: 10.4238/2014]

233 **Wang S**, Chen X, Tang M. MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2. *Oncol Rep* 2014; **32**: 2824-2830 [PMID: 25220761 DOI: 10.3892/or.2014.3478]

234 **Kumar V**, Mondal G, Slavik P, Rachagani S, Batra SK, Mahato RI. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. *Mol Pharm* 2015; **12**: 1289-1298 [PMID: 25679326 DOI: 10.1021/mp500847s]

235 **Petrova E**, Matevossian A, Resh MD. Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma. *Oncogene* 2015; **34**: 263-268 [PMID: 24469057 DOI: 10.1038/onc.2013.575]

236 **Massó-Vallés D**, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. *Cancer Res* 2015; **75**: 1675-1681 [PMID: 25878147 DOI: 10.1158/0008-5472.CAN-14-2852]

237 **Zhou GX**, Ding XL, Wu SB, Zhang HF, Cao W, Qu LS, Zhang H. Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells. *Oncol Rep* 2015; **33**: 661-668 [PMID: 25483364 DOI: 10.3892/or.2014.3650]

238 **Lui GY**, Kovacevic Z, V Menezes S, Kalinowski DS, Merlot AM, Sahni S, Richardson DR. Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion. *Mol Pharmacol* 2015; **87**: 543-560 [PMID: 25561562 DOI: 10.1124/mol.114.096529]

239 **Khan S**, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N, Singh MM, Jaggi M, Chauhan SC. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. *Cancer Res* 2015; **75**: 2292-2304 [PMID: 25840985 DOI: 10.1158/0008-5472.CAN-14-2397]

240 **Liu QQ**, Chen K, Ye Q, Jiang XH, Sun YW. Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway. *Cancer Cell Int* 2016; **16**: 57 [PMID: 27453691 DOI: 10.1186/s12935-016-0336-z]

241 **Haqq J**, Howells LM, Garcea G, Dennison AR. Targeting pancreatic cancer using a combination of gemcitabine with the omega-3 polyunsaturated fatty acid emulsion, Lipidem™. *Mol Nutr Food Res* 2016; **60**: 1437-1447 [PMID: 26603273 DOI: 10.1002/mnfr.201500755]

242 **Ji T**, Li S, Zhang Y, Lang J, Ding Y, Zhao X, Zhao R, Li Y, Shi J, Hao J, Zhao Y, Nie G. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer. *ACS Appl Mater Interfaces* 2016; **8**: 3438-3445 [PMID: 26759926 DOI: 10.1021/acsami.5b11619]

243 **Delitto D**, Wallet SM, Hughes SJ. Targeting tumor tolerance: A new hope for pancreatic cancer therapy? *Pharmacol Ther* 2016; **166**: 9-29 [PMID: 27343757 DOI: 10.1016/j.pharmthera.2016.06.008]

244 **Heinemann V**, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. *Cancer Treat Rev* 2014; **40**: 118-128 [PMID: 23849556 DOI: 10.1016/j.ctrv.2013.04.004]

**P-Reviewer:** Larentzakis A, Shimizu Y, Peng SY **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** India

**Peer-review report classification**


Grade A (Excellent): A, A

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0




**Figure 1 Morphological changes observed in cultured rat pancreatic stellate cells at different time points after isolation**. A: Quiescent pancreatic stellate cells (PSCs) in culture exhibiting a flattened shape with lipid droplets, 6 Hrs after isolation (× 20); B, C: PSCs showing flattened angular appearance and exhibiting cytoplasmic extensions with lipid droplets after 24 and 48hrs respectively in cultures (× 20); D: PSCs exhibiting dense lipid droplets (lipid droplets are indicated with black arrows) in the cytoplasm (× 40); E: Activated PSCs showing long cytoplasmic processes with no lipid droplets in the cytoplasm after 72 h in cultures (× 20); F: Passage 2 rat PSCs in culture, immunostained for α-smooth muscle actin (α-SMA), a cytoskeletal marker for activated PSCs. Red striations indicate α-SMA.




**Figure 2 Fate of activated pancreatic stellate cells.** The fate of activated pancreatic stellate cells (PSCs) could be potentially two pronged- sustained inflammation and/or autocrine mode of PSC activation may perpetuate its activated phenotype, even in the absence of its paracrine triggers, resulting in the development of pancreatic fibrosis or PSCs might undergo either reversion to quiescent phenotype or apoptosis or may become senescent and further cleared by lymphocytes. In the latter situation, there should not be fibrosis.



**Figure 3 Autocrine and paracrine factors mediating pancreatic stellate cells activation.** Cytokines and growth factors secreted by injured acinar cells, immunecells and cancer cells activate the pancreatic stellate cells (PSCs) in a paracrine fashion and stimulatethem to secrete various factors. These factors secreted by PSCs in turn acts in a paracrine fashion and sustains its activation. This autocrine andparacrine signal cycles may help PSCs to retain its activated phenotype,resulting in excess ECM deposition, culminating to pancreatic fibrosis.



**Figure 4 Signaling pathways mediating pancreatic stellate cells activation.** Expression of α-SMA, proliferation, migration and deposition of matrix proteins are the important properties attained by activated pancreatic stellate cells (PSCs) when stimulated with various growth factors and pro inflammatory cytokines. Proliferation and migration is mediated through the MAP kinase and PI3K pathways when PSCs are stimulated with HNE, alcohol, PDGF and IL-33 and other cytokines. TGF-β1 induces the Smad proteins and stimulates the proliferation and collagen secretion by PSCs. Activation of Indian Hedgehog (IHH) signaling in PSCs promotes their migration, proliferation and collagen deposition. PSC mediated Sonic Hedgehog (SHH) signaling promotes cancer cell invasion and migration. Wnt signaling can cause collagen deposition and cancer progression.



**Figure 5 Crosstalk between pancreatic stellate cells and pancreatic cancer cells**. Pancreatic cancer cells (PSCs) promote cancer proliferation, migration, invasion, EMT and metastasis. They also promote the cancer cell survival by decreasing cancer cell apoptosis and helps in chemoresistance. The cancer cells in turn promote PSC proliferation, contractility, migration and increased collagen synthesis. Apart from this, PSCs induce T cell anergy, activate mast cells and promotes endothelial cell proliferation and tube formation. Together, these events mediated by PSCs and pancreatic cancer cells further aggravate pancreatic cancer progression.

**Table 1 Function of pancreatic stellate cells in the quiescent state and after activation**

|  |
| --- |
| **Physiological functions** |
| Store fat and retinoids in their perinuclear droplets, expressing GFAP, desmin and vimentin |
| Secrete MMPs and TIMPs |
| Maintains ECM turnover |
| Involved in maintenance of pancreatic tissue architecture |
| No or limited secretion of cytokines, chemokines and growth factors |
| Function as an immune, progenitor and intermediary cell |
| Possible role in exocrine and endocrine secretions |
| **Pathological functions** |
| Exhibit cell proliferation and migration |
| Deranged ECM turnover due to loss of balance between MMPs and TIMPs |
| Secrete various cytokines, chemokines and growth factors and thereby contribute to inflammatory milieu |
| Stimulate cancer cell proliferation and migration and inhibit their apoptosis |
| Mediate invasion and metastasis of carcinoma cells |
| Mediate chemoresistance and radioresistance thereby promoting cancer cell survival |
| Contribute to the hypovascular and hypoxic tumour microenvironment |
| Promote angiogenesis, neural invasion and epithelial to mesenchymal transition |
| Release neurotransmitters such as acetylcholine and NGF |

GFAP: Glial fibrillary acidic protein; MMPs: Matrix metalloproteinases; TIMPs: Tissue inhibitors of matrix metalloproteinases.

**Table 2 Therapeutic agents that have been used in experimental for inhibition of Pancreatic stellate cells in chronic pancreatitis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Agent** | **Class/Type of agent** | ***In vivo/In vitro* (Study) Model** | **Outcome of the study** |
| F. Nakamura *et al*[169]2000 | FOY-007  FOY-305 | Synthetic serine protease inhibitor | Cytokine stimulated human periacinar fibroblast like cells | Both attenuated proliferation and procollagen type I C-terminal peptide (PIP).  FOY-007 also inhibited collagen synthesis. |
| Xie *et al*[170] 2002 | IS-741 | Carboxamide derivative | Wistar Bonn/Kobori rats | Suppressed the expression of IL-6 and CINC and pancreatic acute phase proteins (PAP and p8). |
| Kuno *et al*[171] 2003 | Lisinopril | Angiotensin- converting enzyme (ACE) inhibitor | Wistar Bonn/Kobori rats | Increased pancreatic weight and decreased pancreatic MPO and serum ACE activity was observed.  Decrease in serum MCP-1 levels, intra-pancreatic hydroxyproline content was identified.  TGF- β1 mRNA overexpression was suppressed. |
| Yamada *et al*[172] 2003 | Candesartan | Angiotensin II receptor antagonist | Wistar Bonn/Kobori rats | Increased pancreatic weight and expression of angiotensinogen  and angiotensin II receptor type 2 mRNA.  Decreased pancreatic MPO and serum ACE activity and hydroxyl proline content.  Suppressed TGF-β1 mRNA overexpression. |
| A. Masamune *et al*[173] 2003 | Y-27632 and HA-1077 | Rho kinase inhibitors | Isolated PSCs from male Wistar rats | Inhibited α-SMA expression, proliferation, type I collagen production and chemotaxis. |
| Nagashio *et al*[174] 2004 | AdTb-ExR | Adenoviral vector system expressing TGF-β receptor | Caerulein induced CP in BALB/c mice | Reduced the activated PSCs, number of apoptotic acinar cells and fibrosis.  Weight of the pancreas increased. |
| Zhao *et al*[175] 2005 | Mutant MCP-1 | … | DBTC induced CP in Lewis rats | Decreased MCP-1, fibrosis and hydroxyproline levels.  Reduced IL6, TGF-β, IL-1β, MCP-1 and PDGF expression. |
| Gibo *et al*[176] 2005 | Camostat mesilate | Oral protease inhibitor | *In vivo:* DBTC induced CP in Lewis rat  *In vitro:* Culture activated PSCs | *In vivo:* Inflammation, fibrosis and cytokines expression was inhibited.  *In vitro:* PSC proliferation and MCP-1 production was reduced. |
| Yamada *et al*[177] 2005 | Lisinopril and  candesartan | Angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker | Wistar Bonn/Kobori rats | Reduced MPO activity, hydroxyproline content, inflammation and fibrosis in combination therapy.  Suppressed mRNA expression of TGF- β1, PDGF- β and TNF-α. |
| Van Westerloo *et al*[178] 2005 | Troglitazone | PPAR-γ ligand | Caerulein induced experimental CP in female C57BL6 mice | Intrapancreatic fibrosis and hydroxy proline contents were reduced.  Attenuated increase in MPO content and TGF-β1 levels. |
| Reding *et al*[179] 2006 | Rofecoxib | COX-2 inhibitor | Wistar Bonn/Kobori rats | Reduced TGF-β, collagen synthesis, inflammation and macrophage infiltration. |
| Asaumi *et al*[180] 2006 | Epigallocatechin-3-gallate EGCG | Antioxidant of polyphenols | Ethanol stimulated PSCs isolated from Wistar rats | Inhibited lipid peroxidation, SOD activity and p38 phosphorylation.  Decreased TGF-β1 and collagen secretion. |
| Baumert *et al*[181] 2005  B. Fitzner *et al*182] 2006[ | IFN-γ | Antifibrotic cytokine | Culture activated PSCs, isolated from LEW.1W rats and  Pancreatic stellate cell lines | Diminished PSC proliferation and collagen synthesis.  Inhibited α-SMA expression.  Induction of quiescent phenotype mediated through activated STAT1. |
| Ohashi *et al*[183] 2006 | Thioredoxin-1 (TRX-1) | Redox-regulating protein with antioxidative activity | Caerulein induced CP in wild type C57BL/6 mice and  transgenic mice overexpressing TRX-1 | Attenuated PSC activation and fibrosis.  TGF-β1 and PDGF expression was reduced.  Lower levels MCP-1 in serum and acinar cells. |
| Mc Carroll *et al*[184] 2006 | Retinol and its metabolites | Vitamers of vitamin A | Ethanol stimulated culture activated rat PSCs | Inhibited PSC activation, proliferation, expression of collagen I. All MAP kinases were activated. |
| Tasci *et al*[185] 2007 | Allopurinol | Xanthine oxidase inhibitor | Trinitrobenzene sulfonic acid (TNBS) induced CP in Sprague-Dawley rats | PSC activation as inhibited *in vivo*.  Lower collagen deposition and lobular and sub-lobular atrophy was observed. |
| Xin-Liang Lu *et al*[186] 2007 | Ascorbic acid | Antioxidant | DBTC induced CP in Sprague-Dawley rats | Decreased malondialdehyde (MDA), hyaluronic acid, laminin concentrations and pancreatic injury.  Increased superoxide dismutase activity. |
| A Shirahige *et al*[187]2007 | Taurine | Amino sulfonic acid | DBTC induced pancreatic fibrosis in Wistar rats  Culture activated PSCs from Wistar rats | Improved pancreatic fibrosis in rats. Increased IL-6 and decreased IL-2 were observed in pancreatic tissue homogenates.  PSC culture supernatants showed decreased type I collagen, MMP-2 and TGF-β1. |
| Rickmann *et al*[188]2007 | Tocotrienols | Vitamin E family members | Culture activated PSCs isolated from Wistar rats | Reduced viability of activated PSCs by apoptosis and autophagy. |
| Michalski CW *et al*[189] 2008 | Canabinoid WIN 55,212-2 | Aminoalkylindole derivative | Human PSCs from CP tissues | Reduced fibronectin, collagen1 and α-SMA levels.  Decreased IL-6, MCP-1 and MMP-2 secretion and invasiveness by PSCs. |
| Weylandt *et al*[190] 2008 | Omega-3 polyunsaturated fatty acids (n-3 PUFA ) | Polyunsaturated fats. | Caerulein-induced CP in fat-1 transgenic mice | Increased n-3 PUFA tissue levels.  Decreased PSC activation.  Less pancreatic fibrosis and collagen content. |
| Karatas *et al*[191] 2008 | Halofuginone | Synthetic halogenated derivative of febrifugine | Complete pancreatic duct obstruction and caerulein hyperstimulation in female Wistar rats | Lower serum amylase, lipase, hyaluronic acid, nitric oxide levels and tissue hydroxyproline levels.  Pancreatic inflammation and acinar cell atrophy was reduced. |
| Brit Fitzner *et al*[192] 2008 | Bosentan | ET-1-receptor antagonist | Culture activated rat PSCs | Inhibited PSC proliferation and collagen synthesis.  Reduced the expression of ET-1, α-SMA and CTGF. |
| Schwer *et al*[193] 2010 | Carbon monoxide-releasing molecules-2 (CORMs) | Metal carbonyl compounds delivering carbon monoxide | Culture activated PSCs isolated from Wistar rats | PSC proliferation was inhibited through p38/HO-1 pathway activation. |
| Nathan *et al*[194] 2010 | Pancreatic secretory trypsin inhibitor (PSTI) |  | Caerulein induced CP in C57Bl/6 PSTI transgenic mice | Decreased MPO activity and inflammatory cell infiltration  Reduction in collagen I and fibronectin mRNA levels. |
| González AM *et al*[195] 2011 | Palm oil tocotrienol-rich fraction | Vitamin E family members | Arginine induced chronic like pancreatitis in Wistar rats | Reduced amylase, hydroxyproline and TGF-β1 levels were observed.  Diminished α-SMA, fibronectin and collagen expression was identified. |
| Long *et al*[196] 2011 | Octreotide | Analog of somatostatin | PSC induced Pancreas Graft Fibrosis in Rats (Sprague Dawley rats as donors and Wistar rats as recipients)  PSCs isolated from Sprague Dawley rats | *In vivo:* Reduced inflammatory cell infiltration and expression  of α-SMA, collagen I and TGF-β1.  *In vitro:* PSC proliferation and activation was inhibited. |
| L.li *et al*[197] 2011 | Pancreatic stone protein ⁄ regenerating protein | Secretory stress  proteins family | Culture activated PSCs from human CP tissue obtained by outgrowth method | Inhibited PSC proliferation, migration and reduced. collagen I and fibronectin.  Increased MMP/TIMP ratio and promoted fibrolysis. |
| Yu Tang *et al*[198]2011 | Sinisan | Chinese herb | TNBS induced CP in Sprague–Dawley rats | Decreased serum amylase.  mRNA expression of TNF-α, IL-1β and COX-2 were reduced and IL-10 was increased.  α -SMA expression was reduced. |
| Wei *et al*[199] 2011 | Pravastatin | Competitive inhibitor of HMG-CoA | Pancreatic ductal  hypertension induced CP in Wistar rats | Attenuated fibrosis and mRNA levels of TNF-α and TGF-β1 and increased IL-10 expression.  Exocrine secretion was improved.  SOD activity was increased. |
| Li *et al*[200] 2011 | α-Tocopherol | Vitamin E family member | TNBS induced CP in Sprague–Dawley rats | Reduced fibrosis and enhanced survival rate.  Pancreatic weight was increased in CP model. |
| Monteiro *et al*[201] 2012 | Vitamin E supplementation |  | Ethanol induced (alcoholic) CP in Wistar rats | mRNA levels of α-SMA, COX-2, IL-6, MIP-3α and TNF-α were decreased and PAP was increased. |
| Matsushita *et al*[202] 2012 | Taurine | Amino sulfonic acid | *In vivo:* DBTC induced CP in Wistar rats  *In vitro:* AR42J acinar cell | Inhibited acinar cell apoptosis. |
| Yang *et al*[203] 2012 | L-Cysteine | Amino acid | *In vivo:* TNBS induced CP in Sprague–Dawley rats  *In vitro:* Culture activated PSCs | Decreased α-SMA, TIMP-1, IL-1β TGF-β1 expression and hydroxylproline levels and increased MMP-2 levels.  Suppressed PSC proliferation and ECM synthesis. |
| Bai *et al*[204] 2012 | Sulindac | Non-steroidal  anti-inflammatory drug | Caerulein induced CP in C57BL/6 mice | Reduced fibrosis, acinar cell loss and inflammatory cell infiltration.  TNF-α and MCP-1 levels were decreased.  Expression of TGF-β, PDGF-β, SHH and Gli was reduced. |
| Lee *et al*[205] 2012 | Simvastatin and Troglitazone | HMG-CoA reductase inhibitor and PPAR agonists | Culture activated PSCs isolated from Sprague-Dawley rats | PSC proliferation was inhibited synergistically. |
| Shen *et al*[206] 2013 | rCXCL9 | Chemokine | *In vivo:* TNBS induced CP in Sprague–Dawley rats  *In vitro:* Culture activated PSCs from  Sprague-Dawley rats | *In vivo:* reduced fibrosis.  *In vivo:* protein expression of collagen 1α1 and TGF-β1 decreased. |
| Gao *et al*[207] 2013 | Bone morphogeneic proteins | TGF-β superfamily members, | *In vivo:* Caerulein induced CP in female Swiss Webster mice  *In vitro:* PSCs isolated from female Swiss Webster mice and human pancreatic tissue | *In vivo:* BMP2 protein levels were increased.  *In vitro:* PSC pre-treatment with BMP2 attenuated TGF-β1, α-SMA, fibronectin and collagen type Iα expression. |
| Zhou *et al*[208]2013 | Edaravone | Free radical scavenger | DBTC induced CP in Sprague–Dawley rats | Rats body weight was improved and reduced the fibrosis.  SOD activity was increased and MDA levels were decreased.  TGF-β, TNF-α and IL-6 levels were down regulated.  NF-κB and PSC activation was inhibited. |
| Niina *et al*[209]2014 | ONO-1301 | Prostacyclin agonist, | DBTC induced CP in Lewis rats | Reduced interstitial fibrosis and inflammatory cell infiltration.  Increased HGF and decreased IL-1β, TNF-α, TGF-β, MCP-1 and collagen mRNA expression was observed. |
| Mrazek *et al*[210] 2015 | Apigenin | Hydroxyflavone | *In vivo:* Caerulein induced pancreatitis in C57/BL6 mice  *In vitro:* PSCs isolated from human pancreatic tissues | *In vivo:* Reduced pancreatic fibrosis and retained acinar cell morphology.  *In vitro:* Induced PSC apoptosis and death.  Down regulated the parathyroid hormone related protein induced fibronectin, collagen 1α1, PCNA, TGF-β and IL-6 expression. |
| Tsang *et al*[211] 2015 | *Trans*-resveratrol | Natural stilbenoid | Rat pancreatic stellate cell line LTC-14 | Collagen type I, α-SMA and fibronectin was down regulated both at mRNA and protein level.  NF-κB activation was decreased. |
| Lin *et al*[212] 2015 | Rhein, Emodin,  and Curcumin | Phenolic compounds | Rat pancreatic stellate cell line LTC-14 | Collagen type I, α-SMA and fibronectin expression was decreased. |
| Gundewar *et al*[213] 2015 | L49H37 | Curcumin analog | Immortalized human pancreatic stellate cell line | Inhibited PSC proliferation and promoted apoptosis.  Decreased the phosphorylation of ERK1/2. |
| Tsang *et al*[214] 2015 | Eruberin A | Flavanol glycoside | Rat PSC line LTC-14 | Inhibited expression of α-SMA Collagen type I and fibronectin. Reduced the activation of NF-κB and phosphorylation PI3K/AKT. |
| Blauer *et al*[215] 2015 | 1,25-dihydroxyvitamin D3 | Vitamin D metabolite | PSCs isolated from C57BL6JOlaHsd mouse | Antiproliferative and antifibrotic effects were observed. |
| Xiao *et al*[216] 2015 | Retinoic acid | Vitamin A Metabolite | *In vivo:* Caerulein induced CP in Balb/c mice  *In vitro:* Culture activated PSCs | Decreased expression of TGF-βRII, collagen 1α1 PDGF-Rβ and β-catenin.  Nuclear translation of β-catenin was decreased.  Wnt 2 and β-catenin protein expression was down regulated.  Inhibited PSC proliferation and induced apoptosis. |
| Witteck *et al*[217] 2015 | Trametinib and  dactolisib | MEK inhibitor and  PI3kinase/mTOR inhibitor | Culture activated PSCs isolated from Lewis rats | Both drugs inhibited PSC proliferation.  Trametinib suppressed the expression of IL-6 and TGF-β1.  Dactolisib decreased the levels of α-SMA and Collagen type Iα1. |
| Ulmasov *et al*[218] 2016 | CWHM-12 (RGD peptidomimetic compound) | Integrin inhibitor | *In vivo:* Caerulein induced pancreatitis in C57/BL6 mice  *In vitro:* Rat PSC line LTC-14 | Pancreatic fibrosis, acinar cell atrophy and loss was reduced.  Decreased the expression of TGF-β regulated genes and PSC activation. |

DBTC: Dibutyltin dichloride; MPO: Myeloperoxidase; SOD: Superoxide dismutase; TNBS: Trinitrobenzene sulfonic acid; MDA: Malondialdehyde; HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; MIP: Macrophage inflammatory protein-3; PCNA: Proliferating cell nuclear antigen.

**Table 3 Therapeutic agents that have been evaluated in experimental/pre-clinical studies to target pancreatic stellate cells and cancer stroma in pancreatic ductal adenocarcinoma**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Agent** | **Class/Type of agent** | ***In vivo/In vitro* (Study) Model** | **Outcome of the study** |
| Feldmann *et al*[219] 2007 | Cyclopamine | Steroidal alkaloid | Orthotopic xenograft model | Inhibited cancer cell invasion and metastasis by suppressing hedgehog. |
| Diep *et al*[220] 2011 | Erlotinib  RDEA119 and AZD6244 | EGFR tyrosine  Kinase and  MAP kinase inhibitors | *In vitro:* Pancreatic cancer cell lines  *In vivo:* BxPC-3 and MIA PaCa-2 mice xenograft model | Inhibited cancer cell proliferation, EGF receptor signaling and induced apoptosis.  Suppressed tumour growth. |
| Froeling *et al*[221] 2011 | ATRA, 9-cis-RA and 13-cis-RA | Metabolites of vitamin A | *In vivo:*  *LSL-KrasG12D/+;LSL-Trp53R172H/*+*;Pdx-1-Cre* mice  *In vitro:* AsPc1 and Capan1 pancreatic cancer cell lines, PS1 and other PSC cell lines | Retinoic acid induced PSC quiescence and decreased migration.  Decreased and induced proliferation and apoptosis of cancer cells. |
| [Chauhan](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chauhan%20VP%5BAuthor%5D&cauthor=true&cauthor_uid=24084631)  *et al*[222] 2013 | Losartan | Angiotensin inhibitor | Orthotopic mice model | Reduced stromal collagen production, expression of TGF-β1, CCN2 and ET-1  Improved drug and oxygen delivery to tumour. |
| Sun *et al*[223] 2013 | Curcumin | Phenolic compound | TGF-β1 stimulated PANC-1 cell line | Inhibited proliferation and promoted apoptosis.  Cancer cell invasion and migration was decreased. |
| [Edderkaoui](http://www.ncbi.nlm.nih.gov/pubmed/?term=Edderkaoui%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24127740) *et al*[224] 2013 | Ellagic acid  Embelin | Polyphenolic and benzoquinone phytochemical | Pancreatic cancer cells and PSCs | Induced apoptosis and inhibited proliferation.  NF-κB activity was decreased. |
| [Macha](http://www.ncbi.nlm.nih.gov/pubmed/?term=Macha%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=23920124)  *et al*[225] 2013 | Guggulsterone | Plant polyphenol | CD18/HPAF and Capan1 cell clones | Inhibited growth and colony formation.  Induced apoptosis and arrested cell cycle.  Decreased motility and invasion. |
| Kozono *et al*[226]2013 | Pirfenidone | Pyridone compound | *In vivo:* Orthotopic tumour mice Model  *In vitro:* PSCs isolated from pancreatic tissue | *In vivo:* Reduced tumour growth, PSC  proliferation and the deposition of collagen type I and periostin in tumours was decreased.  *In vitro:* Proliferation, invasiveness and migration of PSCs was inhibited. |
| Guan *et al*[227] 2014 | Retinoic acid | Vitamin A derivative | Panc-1 and Aspc-1 cell lines  Cancer associated fibroblasts | Reduced α-SMA, FAP and IL-6 expression.  Inhibited cancer cell migration and EMT. |
| Gonzalez-Villasana *et al*[228] 2014 | Bisphosphonates and nab-paclitaxel | Monocyte-macrophage lineage inhibitors | *In vitro:* Human PSCs and cancer cell line  *In vivo:* Orthotopic mice model | *In vitro:* Inhibited PSC activation, proliferation MCP-1 release and  collagen 1 expression and induced apoptosis.  *In vivo:* Reduced tumour size, fibrosis, proliferation and increased apoptosis. |
| Pomianowska *et al*[229] 2014 | Prostaglandin E2 (PGE2) | Lipid compound | Human PSCs isolated from resected pancreatic tumour tissue | IL-1β and EGF induced COX-2 expression, TGF-β induced collagen synthesis and PDGF induced PSC proliferation was inhibited. |
| Gong *et al*[230] 2014 | Nexrutine | Phytoceutical with COX-2 Inhibitor activity | *In vitro:* pancreatic cancer cell lines  *In vivo:* BK5–COX-2 transgenic mice | *In vitro:* promoted cancer cell apoptosis and reduced their growth. Suppressed COX-2 expression.  *In vivo:* NF-κB and Stat3 activity and fibrosis was decreased. |
| Yan *et al*[231] 2014 | Crizotinib | c-MET/ HGF receptor and ALK tyrosine kinases inhibitor | *In vitro:* Human pancreatic cancer cell lines AsPC-1, PANC-1, MIA PaCa-2 and Capan-1  *In vivo:* Mouse xenograft model | *In vitro:* Growth and proliferation was inhibited. Induced apoptosis. Inhibited ALK activity.  *In vivo:* Inhibited angiogenesis, tumour growth and ALK activity. |
| Zhang *et al*[232] 2014 | 5-Azacytidine | Cytidine analogue | Bxpc-3 cancer cell line | Inhibited cancer cell proliferation by suppressing Wnt/β-catenin signaling. |
| Wang *et al*[233] 2014 | miR-216a | MicroRNA | *In vitro:* Capan-2 and PANC-1 pancreatic cancer cell lines  *In vivo:* BALB/c nude mice | *In vitro:*  Inhibited cell growth and induced apoptosis.  Down regulated survivin and XIAP expression.  *In vivo:* Inhibited xenograft tumour growth by suppressing JAK2/STAT3 signaling pathway. |
| Kumar *et al*[234] 2015 | miR-let7b and  GDC-0449 | MicroRNA and Hedgehog inhibitor | *In vitro:* Capan-1, HPAF-II, T3M4 and MIA PaCa-2 cell lines  *In vivo: A*thymic nude mice bearing ectopic tumour | *In vitro:* Decreased cell proliferation and induced apoptosis via GLI dependent mechanism.  *In vivo:* Reduced tumour cell proliferation with increased apoptosis and tumour growth was inhibited. |
| Petrova *et al*[235] 2015 | RU-SKI 43 | Hedgehog acyltransferase inhibitor | *In vitro:* Pancreatic cancer cell lines  *In vivo:* Panc-1 xenograft mouse model | *In vitro:* Reduced cancer cell proliferation and Gli-1 activation through Smo independent signaling.  Decreased Akt and mTOR activity.  *In vivo:* Tumour growth decreased. |
| Massó-Vallés *et al*[236] 2015 | Ibrutinib | Tyrosine kinase inhibitor | Transgenic mouse and xenograft mice models | Reduced fibrosis and extended survival. |
| Zhou *et al*[237] 2015 | Zileuton | 5-LOX inhibitor | Pancreatic cancer SW1990 cell line | Induced apoptosis, decreased proliferation and expression of 5-lipoxygenase. |
| Lui *et al*[238] 2015 | Desferrioxamine,  Di-2-pyridylketone-  4,4-dimethyl-3-thiosemicarbazone  and Di-2-pyridylketone  4-cyclohexyl-4-methyl-3-thiosemicarbazone | Thiosemicarbazones | *In vitro:* PANC-1 and MIAPaCa- 2  *In vivo:* PANC-1 tumour xenograft mice | Activation of the non-receptor tyrosine kinase Src and cAbl was decreased *in vitro* and STAT3 activation was reduced in both *in vivo* and in vitro condition. |
| Khan *et al*[239] 2015 | Ormeloxifene | Nonsteroidal drug | Pancreatic cancer cell lines and PDAC xenograft mice | Inhibited cell proliferation, tumour stroma through SHH pathway and stromal cell infiltration.  Decreased collagen I expression.  Restored the tumour-suppressor miR-132 expression. |
| Liu *et al*[240] 2016 | Oridonin | Tetracycline diterpenoid compound | Aspc1, Bxpc3, Panc1 and SW1990 cell lines | Migration and EMT was inhibited by affecting Wnt/β-catenin signal events. |
| Haqq *et al*[241] 2016 | Gemcitabine with omega-3 polyunsaturated fatty acid emulsion, (LipidemTM) | Nucleoside analog | *In vitro* studies using pancreatic cancer cell lines Capan-1 and Panc-1 and PSC cell line; RLT-PSC | Drugs showed antiproliferative and anti-invasive effects. |
| Ji *et al*[242] 2016 | MMP‑2 responsive liposome loaded with Pirfenidone and gemcitabine | --- | *In vivo:* BALB/c nude Orthotopic tumour mice model  In vitro: Human PSCs isolated from surgical specimens of Pancreatic cancer | Pirfenidone inhibited collagen I and TGF-β expression in PSCs  Gemcitabine killed pancreatic tumour cells. |

ALK: Anaplastic lymphoma kinase; XIAP: X-linked inhibitor of apoptosis protein; mTOR: Mechanistic target of rapamycin.